Individual Insurance Market Performance in 2018

Authors: Cynthia Cox, Rachel Fehr, and Larry Levitt
Published: May 7, 2019

Issue Brief

Note: An analysis of first quarter 2019 data for the individual insurance market is available here.

The early years of the Affordable Care Act (ACA) exchanges and broader ACA-compliant individual market were marked by volatility. Markets in some parts of the country have remained fragile, with little competition, an insufficient number of healthy enrollees to balance those who are sick, and high premiums as a result. By 2017, however, the individual market generally had begun to stabilize. Absent any policy changes, it is likely insurers would have required only modest premium increases to regain or maintain profitability in 2018.

However, by mid-2017 when insurers were considering 2018 premiums and participation, it was unclear whether the individual mandate would be enforced, cost-sharing subsidies would be paid, or the ACA as a whole would remain law. In October 2017, the Trump Administration ceased payments for cost-sharing subsidies, which led some insurers to exit the market or request larger premium increases than they would have otherwise. The Administration also reduced funding for advertising and outreach. And, Congress ultimately repealed the individual mandate penalty, effective for 2019. Amid these policy changes and legislative uncertainty, insurers raised benchmark premiums by an average of 34% going into 2018.

In this analysis, we find individual market insurers saw better financial performance in 2018 than in all the earlier years of the ACA and returned to, or even exceeded, pre-ACA levels of profitability. Premiums fell slightly on average for 2019, as it became clear that some insurers had raised 2018 rates more than was necessary. It is likely premiums would have fallen even more if the individual mandate penalty were still in effect.

In this brief, we use financial data reported by insurance companies to the National Association of Insurance Commissioners and compiled by Mark Farrah Associates to look at the average premiums, claims, medical loss ratios, gross margins, and enrollee utilization from 2011 through 2018 in the individual insurance market, as well as the amount of medical loss ratio rebates insurers expect to issue to 2018 enrollees. These figures include coverage purchased through the ACA’s exchange marketplaces and ACA-compliant plans purchased directly from insurers outside the marketplaces (which are part of the same risk pool), as well as individual plans originally purchased before the ACA went into effect.

Our analysis also finds that insurers are expecting to pay a record total of about $800 million in rebates to individual market consumers for not meeting the ACA medical loss ratio threshold, which requires them to spend at least 80% of premium revenues on health care claims or quality improvement activities. This comes from initial estimates reported by insurers; actual rebates could end up being either higher or lower. In total, across the individual, small group, and large group markets, insurers expect to issue about $1.4 billion in rebates this year based on their 2018 performance. If insurer expectations hold true, these will be the largest consumer rebates issued since the MLR program began.

These new data from 2018 offer further evidence that insurers in the individual market are regaining profitability, though more recent policy and legislative changes taking effect in 2019 – the repeal of the individual mandate penalty as part of tax reform legislation and the proliferation of loosely-regulated short-term insurance plans – continue to cloud expectations somewhat for the future.

Medical Loss Ratios

As we found in our previous analysis, insurer financial performance as measured by loss ratios (the share of health premiums paid out as claims) worsened in the earliest years of the ACA Marketplaces, but began to improve more recently. This is to be expected, as the market had just undergone significant regulatory changes in 2014 and insurers had very little information to work with in setting their premiums.

The chart below shows simple loss ratios, which differ from the formula used in the ACA’s MLR provision.1  Loss ratios began to decline in 2016, suggesting improved financial performance. In 2017, following relatively large premium increases, individual market insurers saw significant improvement in loss ratios, a sign that individual market insurers on average were beginning to better match premium revenues to claims costs. Loss ratios have continued to decline, averaging 70% in 2018. This suggests insurers were able to build in the loss of cost-sharing subsidy payments when setting premiums and some insurers likely over-corrected.

Figure 1: Average Individual Market Medical Loss Ratios, 2011 – 2018

Margins

Another way to look at individual market financial performance is to examine average gross margins per member per month, or the average amount by which premium income exceeds claims costs per enrollee in a given month. Gross margins are an indicator of performance, but positive margins do not necessarily translate into profitability since they do not account for administrative expenses.

Figure 2: Average Individual Market Gross Margins Per Member Per Month, 2011 – 2018

Gross margins show a similar pattern to loss ratios. Insurer financial performance improved dramatically through 2018 (increasing to $167 per enrollee, from a recent annual low of -$9 in 2015). These data suggest that insurers in this market are now financially healthy, on average.

Driving recent improvements in individual market insurer financial performance are the premium increases in 2018 combined with more modest growth in claims for medical expenses. On average, premiums per enrollee grew 26% from 2017 to 2018, while per person claims grew only 7%. This growth in premiums is in part due to the loss of cost-sharing subsidy payments; insurers are required by law to provide cost-sharing subsidies to eligible enrollees, but are no longer being reimbursed by the federal government. Rate hikes to offset the termination of federal cost-sharing subsidy payments were a major factor in 2018 premium increases.

Figure 3: Average Individual Market Monthly Premiums and Claims Per Person, 2011 – 2018

One concern about rising premiums in the individual market was whether healthy enrollees would drop out of the market in large numbers rather than pay higher rates. While the vast majority of exchange enrollees are subsidized and sheltered from paying premium increases, those enrolling off-exchange would have to pay the full increase. Despite this dynamic, the average number of days individual market enrollees spent in a hospital in 2018 was slightly lower than inpatient days in the previous three years.2 

Figure 4: Average Individual Market Monthly Hospital Patient Days Per 1,000 Enrollees, 2011 – 2018

Taken together, these data on claims and utilization suggest that the individual market risk pool is relatively stable, though sicker on average than the pre-ACA market, which is to be expected since people with pre-existing conditions have guaranteed access to coverage under the ACA. Despite concerns that healthier enrollees may be dropping out of the market in recent years, somewhat lower average inpatient days indicate that the individual market did not get sicker, on average, during 2018.

Expected Rebates

The medical loss ratio (“MLR”) provision of the ACA requires most insurance companies that cover individuals to spend at least 80% of their premium income on health care claims and quality improvement, leaving the remaining 20% for administration, marketing, and profit. Beginning in 2012, insurers failing to meet the applicable MLR standard for the prior year (2011) were required to issue rebates to consumers and employers. Thus far, the 2011 rebates had remained the largest ever issued – totaling $399 million in the individual market alone (and $1.071 billion across the individual, small group, and large group markets).

Insurers’ preliminary estimates indicate they expect to issue about $800 million in rebates to 2018 individual market enrollees, which would be the highest total for the individual market by far since the program began. While this represents initial insurer estimates, and the actual rebate amount issued could be lower or higher3 , these high expected rebates provide further evidence that some insurers over-corrected in raising individual market premiums for 2018.

Insurers estimate more than 3 million 2018 individual market enrollees, or 26%, are eligible to receive rebates. Insurers owing rebates expect to issue about $260 per member, on average. All rebates must be issued by September 30 of the year following the applicable MLR reporting period (i.e., September 2019 for the 2018 reporting period).

Across all commercial markets – individual, small group, and large group – rebates are expected to total approximately $1.4 billion. If insurer estimates hold true, these will be the largest rebates issued since the MLR program began. These higher rebates are mostly driven by the individual market. Rebates in the small and large group markets are expected to be larger than average, but not significantly so.

Discussion

Annual results from 2018 suggest that despite significant challenges and recent enrollment declines, insurers in the individual insurance market are now generally profitable. Insurer financial results from 2018 – after the Administration’s decision to cease cost-sharing subsidy payments, but before the repeal of the individual mandate penalty in the tax overhaul went into effect – reveal the most favorable year in the ACA-compliant market’s history.

Premium and claims data support the notion that 2017 premium increases were necessary as a one-time market correction to adjust for a sicker-than-expected risk pool, and premium increases in 2018 were in large part compensating for policy uncertainty and the termination of cost-sharing subsidy payments, though some insurers appear to have over-compensated. Without these policy changes, it is likely that insurers would generally have required only modest premium increases in 2018. Low loss ratios and higher margins indicate that some insurers raised premiums more than was necessary to cover claims and administrative costs and earn a reasonable profit in 2018.

Across the individual market, insurers expect to pay record-high rebates to consumers for failing to meet the medical loss ratio requirement, providing further evidence that insurers over-corrected when setting 2018 premiums. Before the ACA’s MLR provision went into effect, insurers in such a situation would have experienced windfall profits. The MLR rule requires insurers to repay consumers in the form of a cash rebate or premium credit when the prior year’s premiums are determined to have been too high relative to claims costs.

While markets in some parts of the country remain more fragile, the individual market on average is becoming more profitable. Some insurers have exited the market in recent years, but others have been successful and expanded their footprints, as would be expected in a competitive marketplace. Even though repeal of the individual mandate penalty and expansion of loosely-regulated insurance options had an upward effect on 2019 premiums, premiums actually decreased slightly because 2018 premiums were higher than necessary to cover claims costs. In 2019, new insurers have entered and some insurers are reentering markets they had previously exited. While signups through the marketplace during the 2019 open enrollment period declined somewhat compared to 2018, financial results suggest the market is still stable and sustainable.

Methods

We analyzed insurer-reported financial data from Health Coverage Portal TM, a market database maintained by Mark Farrah Associates, which includes information from the National Association of Insurance Commissioners. The dataset analyzed in this report does not include NAIC plans licensed as life insurance or California HMOs regulated by California’s Department of Managed Health Care; in total, the plans in this dataset represent at least 80% of the individual market. All figures in this issue brief are for the individual health insurance market as a whole, which includes major medical insurance plans and mini-med plans sold both on and off exchange. We excluded some plans that filed negative enrollment, premiums, or claims and corrected for plans that did not file “member months” in the annual statement but did file current year membership.

To calculate the weighted average loss ratio across the individual market, we divided the market-wide sum of total incurred claims by the sum of all unadjusted health premiums earned. Medical loss ratios in this analysis are simple loss ratios and do not adjust for quality improvement expenses, taxes, or risk program payments. Gross margins were calculated by subtracting the sum of total incurred claims from the sum of unadjusted health premiums earned and dividing by the total number of member months (average monthly enrollment) in the individual insurance market. Using earned premiums adjusted for taxes and fees to calculate loss ratios and gross margins increases the MLR by 6 percentage points and decreases the gross margin per member by $42 in 2018. On average across all years, using earned premiums adjusted for taxes and fees increases the MLR by 3 percentage points and decreases the gross margin per member by $14.

Total rebates are based on preliminary estimates from insurers. Since 2014, the total rebate amount issued across the individual, small group and large group markets has varied by 3 to 5% from insurer estimates. At the market level, the difference between estimates and actual rebate totals have been more volatile. Since 2014, individual market estimates have varied by as much as $34 million, or over 20%, as compared to the final actual rebates reported in December of the year following the applicable MLR reporting period. In some years, final rebates are higher than expected and in other years, final rebates are lower.

Endnotes

  1. The loss ratios shown in this issue brief differ from the definition of MLR in the ACA, which makes some adjustments for quality improvement and taxes, and do not account for reinsurance, risk corridors, or risk adjustment payments. Reinsurance payments, in particular, helped offset some losses insurers would have otherwise experienced. However, the ACA’s reinsurance program was temporary, ending in 2016, so loss ratio calculations excluding reinsurance payments are a good indicator of financial stability going forward. ↩︎
  2. Hospital patient days for 2014 are not necessarily representative of the full year because open enrollment was longer that year and a number of exchange enrollees did not begin their coverage until mid-year 2014. ↩︎
  3. See Methods for more discussion on how insurer estimates tend to vary from actual rebate totals. ↩︎
News Release

Beneficiaries Who Switch to Medicare Advantage Have Lower Medicare Spending and Use Fewer Services – In the Prior Year – Than Those Who Stay in Traditional Medicare

Current Medicare Advantage Payment System May Overestimate Expected Costs for Plans

Published: May 7, 2019

Medicare Advantage plans gain beneficiaries from traditional Medicare who have lower average spending and use fewer health services than similar beneficiaries who choose to remain in traditional Medicare, according to a new KFF analysis.

The analysis finds that people who switched from traditional Medicare to Medicare Advantage in 2016 had health spending in 2015 that was $1,253 less, on average, than the average spending for beneficiaries who remained in traditional Medicare (after adjusting for health risk).

The pattern held true even among beneficiaries with specific health conditions, including asthma, breast or prostate cancer and diabetes. For instance, among beneficiaries with diabetes who were in traditional Medicare in 2015, those who switched to Medicare Advantage in 2016 had Medicare spending in 2015 that was $1,072 lower, on average, than similar beneficiaries with diabetes who stayed in traditional Medicare (after adjusting for health risk).

The findings raise questions about whether Medicare Advantage plans tend to attract healthier and lower-cost beneficiaries and whether lower rates of service use among Medicare Advantage enrollees is attributable to care management or self-selection. Most notably, the study findings suggest that the current method of setting payments to Medicare Advantage plans based on spending for people in traditional Medicare may systematically overestimate expected costs of Medicare Advantage enrollees. Adjusting payments to reflect Medicare Advantage enrollees’ prior use of health services could potentially lower total Medicare spending by billions of dollars annually.

Setting payments to more accurately reflect expected costs would have major implications for Medicare spending, as Medicare Advantage plans cover 20 million people, about a third of all Medicare beneficiaries, and enrollment is expected to climb to over 30 million people within the next decade.

Do People Who Sign Up for Medicare Advantage Plans Have Lower Medicare Spending?

Authors: Gretchen Jacobson, Tricia Neuman, and Anthony Damico
Published: May 7, 2019

Key Findings

People on Medicare can choose coverage from either traditional Medicare or Medicare Advantage plans, typically trading off broad access to providers for potentially lower premiums and out-of-pocket costs. Beneficiaries who choose Medicare Advantage may differ from those in traditional Medicare in both measurable and unmeasurable ways, which may influence their use of services and spending. Yet, Medicare payments to Medicare Advantage plans per enrollee are based on average spending among beneficiaries in traditional Medicare.

This analysis looks at whether beneficiaries who choose to enroll in Medicare Advantage plans have lower spending, on average – before they enroll in Medicare Advantage plans – than similar people who remain in traditional Medicare. We compare average traditional Medicare spending and use of services in 2015 among beneficiaries who switched to Medicare Advantage plans in 2016 with those who remained in traditional Medicare that year, after adjusting for health risk. We adjust Medicare spending values for health conditions and other factors, with a model similar to the CMS HCC Risk Adjustment Model that is used to adjust payments to Medicare Advantage plans (see Methods).

Key Findings

  • People who switched from traditional Medicare to Medicare Advantage in 2016 spent $1,253 less in 2015, on average, than beneficiaries who remained in traditional Medicare, after adjusting for health risk (ES Figure).
ES Figure: Traditional Medicare spending was $1,253 lower for beneficiaries who switched to Medicare Advantage in 2016 than for those who did not switch
  • Even among traditional Medicare beneficiaries with specific health conditions, those who shifted to Medicare Advantage in 2016 had lower average spending in 2015, including people with diabetes ($1,072), asthma ($1,410), and breast or prostate cancer ($1,517).

Even after risk adjustment, the results indicate that beneficiaries who choose Medicare Advantage have lower Medicare spending – before they enroll in Medicare Advantage plans – than similar beneficiaries who remain in traditional Medicare, suggesting that basing payments to plans on the spending of those in traditional Medicare may systematically overestimate expected costs of Medicare Advantage enrollees.

Issue Brief

Overview

Medicare payments to Medicare HMOs and PPOs, known as Medicare Advantage plans, have always been based on Medicare spending by similar people in traditional Medicare, partly because Medicare has never had accurate, complete data on the use of services or health care spending for beneficiaries in Medicare Advantage plans.1  The assumption has been that adjusting payments to plans for health status and other factors accounts for differences between beneficiaries in traditional Medicare and those in Medicare Advantage plans. Profits are assumed to be due to plans reducing spending by either managing fees (e.g., by having lower-cost hospitals in their network) or changing patterns of care (e.g., reducing hospital readmissions), rather than to favorable selection. Nonetheless, selection bias has been an ongoing concern and the subject of many studies over the years, with mixed evidence of favorable selection.2 ,3 ,4 ,5 ,6  This question is important because it affects the accuracy of Medicare payments to plans on behalf of 20 million Medicare beneficiaries, and rising.

This is the first known analysis to examine whether beneficiaries who choose to enroll in Medicare Advantage plans have lower spending and use fewer services – before enrolling in Medicare Advantage – than similar people in traditional Medicare. If Medicare Advantage enrollees use fewer services and have lower Medicare spending before they enroll in Medicare Advantage plans, compared to similar beneficiaries in traditional Medicare, then basing payments to Medicare Advantage plans on the Medicare spending for similar beneficiaries in traditional Medicare would overestimate the expected costs of Medicare Advantage enrollees and overpay plans by billions of dollars over the next decade. Studies that have looked at differences in the use of services and Medicare spending for Medicare Advantage enrollees compared to beneficiaries in traditional Medicare that did not account for actual prior differences may have overestimated the extent to which plans are reducing enrollees’ spending or use of services.

To address this question, we examine Medicare Part A and B spending and service use for traditional Medicare beneficiaries in 2015. We compare average Medicare spending and use of services for traditional Medicare beneficiaries who enrolled in Medicare Advantage plans versus those who remained in traditional Medicare in 2016, after adjusting spending values for health conditions and other relevant factors (Figure 1). We examine how the results differ across demographics, chronic conditions, and counties, and also examine how the results change when Part D spending is included. The analysis is based on a five percent sample of Medicare claims data and excludes beneficiaries who may not have been active choosers in 2016; more details about the analysis are included in the Methods.

Figure 1: Study Overview

Differences in Medicare Spending

Among beneficiaries in traditional Medicare in 2015, those who enrolled in Medicare Advantage in 2016 had spending (for Part A and Part B) that was $1,253 lower (13% difference), on average, than beneficiaries who remained in traditional Medicare in 2016, after adjusting for health risk factors (Figure 2; Tables 1 and 2).7 

Figure 2: Traditional Medicare spending was $1,253 lower for beneficiaries who switched to Medicare Advantage in 2016 than for those who did not switch

When Part D spending is included, the results changed only slightly. Traditional Medicare beneficiaries in 2015 who switched to Medicare Advantage in 2016 had total Medicare spending (including Part D) that was 15 percent lower than spending for beneficiaries who remained in traditional Medicare in 2016.

Comparison to Other Payments Received by Medicare Advantage Plans. To put the difference in Medicare spending in context, the $1,253 average difference in spending is nearly four-times larger than the average per capita quality-based bonus payment ($336) paid to Medicare Advantage prescription drugs plans that qualified for bonuses in 2015 (Figure 3). The average difference in spending is also more than twice as large as the average annual premium paid by Medicare Advantage enrollees in 2015, including enrollees in plans with no premium.

Figure 3: Potential overpayments per enrollee were almost 4 times larger than the average per enrollee quality-based bonus paid to Medicare Advantage plans in 2015

Differences in Medicare Spending, by Demographics

Traditional Medicare spending in 2015 was lower for beneficiaries who enrolled in Medicare Advantage plans in 2016 than for similar beneficiaries who remained in traditional Medicare that year, by age and gender, and among beneficiaries dually eligible for Medicare and Medicaid, after adjusting for health risk and other factors (Table 1).

  • Age: The difference in average traditional Medicare spending in 2015 among beneficiaries who switched to Medicare Advantage in 2016, compared to those who remained in traditional Medicare, was evident for beneficiaries of all ages, and increased with age for beneficiaries over the age of 65, after risk adjustment. For example, among beneficiaries ages 65-69, average traditional Medicare spending in 2015 was $1,119 lower among beneficiaries who switched to a Medicare Advantage plan in 2016 than for similar beneficiaries who remained in traditional Medicare; among beneficiaries ages 85-89, the difference in spending was $1,314. This finding suggests that selection bias, and the associated potential overpayments, may increase with age.
  • Gender: The average difference in spending between the two groups was similar among men and women ($1,271 and $1,247, respectively).
  • Dual eligibility for Medicaid: Traditional Medicare spending in 2015 for Medicare beneficiaries with full Medicaid benefits (full dual eligible) who enrolled in Medicare Advantage in 2016 was $1,142 lower, on average, than spending for similar full dual eligibles who stayed in traditional Medicare in 2016, after adjusting for health and demographic factors. Similarly, partial dual eligibles who enrolled in Medicare Advantage in 2016 had traditional Medicare spending in 2015 that was $1,162 lower than spending for those who remained in traditional Medicare in 2016, after adjusting for risk factors. In other words, among dually eligible beneficiaries – a group of beneficiaries with relatively high Medicare spending – those who used more services and incurred higher Medicare spending in 2015 were more likely to remain in traditional Medicare in 2016 while dual eligibles with lower service use and spending were more likely to enroll in a Medicare Advantage plan in 2016.
  • Institutional status: Among Medicare beneficiaries living in institutions, such as nursing homes, traditional Medicare spending in 2015 was $1,825 lower among those who enrolled in Medicare Advantage plans in 2016 than among similar institutional residents who stayed in traditional Medicare that year. If higher-cost nursing home residents are remaining in traditional Medicare while lower-cost residents are moving to Medicare Advantage plans, it could make it easier for Medicare Advantage plans serving the nursing home population to be profitable, which may explain the relatively recent increase in firms offering Special Needs Plans for this population (I-SNPs).8  

Differences in Medicare Spending, by Chronic Conditions

Even among beneficiaries with the same chronic conditions, those who enrolled in Medicare Advantage plans in 2016 consistently had lower Medicare spending in 2015 than similar beneficiaries who remained in traditional Medicare in 2016 (Table 1).

For example, among traditional Medicare beneficiaries with diabetes in 2015, those who enrolled in Medicare Advantage plans in 2016 had Medicare spending that was $1,072 lower in 2015, on average, than similar beneficiaries with diabetes who stayed in traditional Medicare in 2016, after adjusting for differences in health status (Figure 4). In other words, it would appear that lower-cost beneficiaries with diabetes are more inclined to enroll in Medicare Advantage than higher-cost diabetics. Likewise, traditional Medicare beneficiaries with asthma who enrolled in Medicare Advantage plans in 2016 had Medicare spending that was $1,410 lower in 2015, on average, than similar beneficiaries with asthma who remained in traditional Medicare in 2016, even after adjusting for health risk factors.

Figure 4: Beneficiaries with asthma who switched to Medicare Advantage had traditional Medicare spending that was $1,410 lower, on average, than similar beneficiaries who did not switch

The difference in average, adjusted 2015 traditional Medicare spending between beneficiaries who subsequently enrolled in Medicare Advantage versus those who remained in traditional Medicare increases with the number of chronic conditions, rising from $226 among those with no chronic conditions to $1,629 or more among beneficiaries with 5 or more chronic conditions (Figure 5). This finding suggests that potential overpayments may be largest for the Medicare Advantage plans that are serving the sickest beneficiaries.

Figure 5: Potential overpayments for Medicare Advantage enrollees increased with the number of chronic conditions

Differences in Medicare Spending, by County

In this section, we looked at whether the observed differences in spending and service use persist across markets, and the extent to which differences may vary from one market to another. We compared average spending in 2015 among beneficiaries who switched to Medicare Advantage in 2016 versus those who remained in traditional Medicare, without adjusting for other factors. We were not able to replicate the analysis by county with the adjustment for risk factors, such as health conditions and demographics, due to sample size constraints. For this analysis, we looked at 20 relatively large markets that vary geographically, and vary by Medicare Advantage penetration and payment quartiles.

Among large, urban counties, the differences in spending between Medicare Advantage enrollees and beneficiaries in traditional Medicare varied greatly across the country (Figure 6; Table 3). In some counties, such as Los Angeles, CA, San Bernardino, CA, Wayne, MI (Detroit), and Cuyahoga, OH (Cleveland), beneficiaries who enrolled in Medicare Advantage plans in 2016 had significantly lower traditional Medicare spending in 2015 ( ≥$3,000 lower) than beneficiaries in the county who remained in traditional Medicare in 2016.

Figure 6: The average difference in traditional Medicare spending in 2015 for beneficiaries who switched to Medicare Advantage versus stayed in traditional Medicare in 2016 varied greatly across the country

In other counties, such as Allegheny, PA (Pittsburgh), Baltimore City, MD, Mecklenburg, NC (Charlotte), Erie, NY (Buffalo), and Multnomah, OR (Portland) beneficiaries who enrolled in Medicare Advantage plans in 2016 had higher prior year traditional Medicare spending ( ≤-$1,000) than beneficiaries in the county who remained in traditional Medicare in 2016. These differences across counties suggest that the selection bias into Medicare Advantage may vary across markets.

Discussion

This analysis examines whether beneficiaries who choose to enroll in Medicare Advantage plans have lower spending and use fewer services – before enrolling in Medicare Advantage – than similar people in traditional Medicare. The study found that beneficiaries who chose to enroll in a Medicare Advantage plan in 2016 had average expenditures in traditional Medicare (in 2015) that were $1,253 less, on average, than similar beneficiaries who remained in traditional Medicare. Similar differences in spending were found across all demographics and chronic conditions, even after adjusting for health risk factors. The results suggest that favorable self-selection into Medicare Advantage plans is occurring, even among traditional Medicare beneficiaries with similar health conditions. The findings raise questions as to why beneficiaries who are higher utilizers are less likely to go into Medicare Advantage and instead remain in traditional Medicare.

Other studies have examined services used by people while they were enrolled in Medicare Advantage plans, based on limited data, and have generally found that beneficiaries in Medicare Advantage plans use fewer services than those in traditional Medicare.9 ,10 ,11  Notably, the authors of these studies almost universally attribute differences in service utilization to care management by the plans – rather than to pre-existing differences in care seeking behavior and use of health services. This study suggests that differences in health care use, and spending, are evident before beneficiaries decided to enroll in Medicare Advantage plans or remain in traditional Medicare, raising questions about the extent to which plans are actually lowering spending or managing care.

It is not clear whether the differences in spending observed in this study increase, decrease, or persist over time as beneficiaries age, which has implications for whether a similar difference in spending could be assumed for all Medicare Advantage enrollees.12  Likewise, it is not clear how this difference in spending will change as the share of counties with the majority of beneficiaries in Medicare Advantage plans grows. This missing information could have important implications for Medicare spending. Potential overpayments could amount to billions in excess Medicare spending over a ten-year period if the observed differences in spending hold up as beneficiaries age and Medicare Advantage enrollment continues to rise. To illustrate, if the difference in average Medicare spending ($1,253) applied to just 10 percent of all Medicare Advantage enrollees in 2016, or 1.8 million enrollees, it would amount to more than $2 billion in excess spending in one year alone.

Policymakers could consider adjusting payments to reflect Medicare Advantage enrollees’ prior use of health care services, which could lower total Medicare spending and in turn reduce Medicare Part B premiums and deductibles for all beneficiaries. With more than 20 million enrollees in Medicare Advantage plans and Medicare payments to plans projected to reach $250 billion in 2019, the stakes are high for making payments to plans as accurate as possible.13 ,14 

Gretchen Jacobson and Tricia Neuman are with the Kaiser Family Foundation. Anthony Damico is an independent consultant.

This paper benefitted from the methodological expertise of Bianca Frogner at the University of Washington.

Methods

This analysis focuses on beneficiaries in traditional Medicare who were enrolled in both Medicare Part A and Medicare Part B in 2015, examining average adjusted 2015 Medicare Part A and B spending for these beneficiaries, based on their 2016 enrollment in Medicare Advantage plans or traditional Medicare. Beneficiaries who enrolled in Medicare Advantage plans at any point during the 2016 calendar year were categorized as Medicare Advantage enrollees.

To conduct this analysis, we excluded beneficiaries who: (1) became Medicare beneficiaries after 2013 or were not in traditional Medicare with both Part A and Part B in 2013, 2014, and 2015 (5.8 million people) because three years of claims data were required for each person to collect sufficient information about chronic conditions; (2) died prior to January 2016 (1.5 million people) because they would not have had the same opportunity to enroll in Medicare Advantage as other beneficiaries; (3) had end-stage renal disease in 2015 or 2016 (290 thousand people) because the vast majority were not eligible to enroll in a Medicare Advantage plan in 2016; (4) were unlikely to have actively selected (and instead may have been passively enrolled in) a Medicare Advantage plan, including beneficiaries who enrolled in Medicare-Medicaid Plans (MMPs) and employer group health plans (183 thousand people); (5) lived in Puerto Rico and other territories because some elements in the Medicare claims data are not as reliable or accurate for these beneficiaries; (6) enrolled in cost, Medical Savings Account (MSA), or PACE plans in 2016 (21 thousand people) because these plans are paid differently than Medicare Advantage plans; and (7) enrolled in a Special Needs Plan for people with specified chronic conditions (C-SNP; 13 thousand people) because the design of these plans may disproportionately attract healthier people with chronic conditions. When we relaxed the first inclusion requirement, for beneficiaries to be in traditional Medicare with both Part A and Part B in 2013, 2014, and 2015, and instead only required included beneficiaries to be in traditional Medicare with Part A and B in 2014 and 2015, the findings did not materially change, with the adjusted percent difference in spending remaining 13%. Similarly, when we included people in C-SNPs, the adjusted percent difference in spending did not change. In total, the primary analysis included 24 million beneficiaries who were in traditional Medicare in 2015.

The brief uses claims data from a five percent sample of Medicare beneficiaries from the Master Beneficiary Summary Files of CMS’s Chronic Conditions Data Warehouse for 2013 through 2016. The analysis first examined the bivariate differences in spending and use of services by demographics, chronic conditions, and other factors. To control for differences in health status and other factors that could account for the difference in Medicare spending, a multivariate generalized linear log link model with a gamma distribution was developed that mimics as closely as possible the CMS-HCC Risk Adjustment Model, which is used to risk-adjust payments to Medicare Advantage plans. The model for this study includes the same structure of the demographic variables and interaction terms as the HCC Risk Adjustment Model. This study’s model also includes the only available (although imperfect) variable to indicate whether someone who used a Part D covered drug was residing in a long-term care facility at any point during the year; this approach misses information about institutional residency status for the people who do not take drugs covered under Part D.

This study examined bivariate differences in traditional Medicare spending across counties, for those county residents who enrolled in Medicare Advantage compared to those who did not. The data used in the study did not include a sufficient number of people to adjust these county-level values for health risk factors. Future studies could examine whether the observed bivariate differences across counties hold, after adjusting for health risk factors.

The model used in this analysis does not include the HCCs in the Risk Adjustment Model that are not recorded as chronic conditions in the Chronic Conditions Data Warehouse, the majority of which are HCCs for acute or relatively rare conditions. The margins command, with values as observed, was used to generate the adjusted spending values. Alternative models for this analysis also included as covariates the per capita traditional Medicare spending for each county, beneficiaries’ race/ethnicity as defined by the RTI race variable, and additional chronic conditions, with no meaningful change in the results. We also looked at the sensitivity of the findings to the inclusion criteria; when we included beneficiaries who were in traditional Medicare with Part A and B in 2014 and 2015 but either were not in traditional Medicare or did not have both Part A and Part B in 2013, the findings did not materially change, with the risk adjusted difference in spending rising from $1,253 to $1,298.

Tables

Table 1. Average Traditional Medicare Spending in 2015 for Beneficiaries who Switched to Medicare Advantage Or Stayed in Traditional Medicare in 2016, After Adjusting for Health Risk Factors
Characteristics in 2015People who stayed in TM in 2016People who switched to MA in 2016Difference in spending, 2015
Number of peopleAverage Part A & B spending, 2015Number of peopleAverage Part A & B spending, 2015
Overall23,714,780$9,362443,240$8,109$1,253
Age
Under 35314,880$8,6318,220$7,476$1,155
35-44527,740$8,77815,020$7,603$1,175
45-541,030,820$8,54936,140$7,405$1,144
55-59801,600$8,36231,180$7,243$1,119
60-64904,460$8,10841,120$7,023$1,085
65-693,360,240$8,36579,480$7,246$1,119
70-745,598,560$9,22996,280$7,994$1,235
75-794,341,380$9,59263,060$8,309$1,284
80-843,175,960$9,68737,900$8,391$1,296
85-892,218,880$9,81921,260$8,505$1,314
90-941,089,460$10,23510,340$8,865$1,370
95 and older350,800$11,4093,240$9,883$1,527
Dual eligibility
Non-dual eligible19,132,740$9,779281,300$8,471$1,309
Partial dual eligible1,257,160$8,53661,580$7,394$1,142
Full dual eligible3,324,880$8,681100,360$7,520$1,162
Original reason for eligibility
Disabled5,757,400$9,234190,840$7,999$1,236
Aged17,957,380$9,471252,400$8,204$1,267
Gender
Female13,211,740$9,320240,420$8,073$1,247
Male10,503,040$9,500202,820$8,229$1,271
Institutional status
Community resident13,363,540$9,684267,420$8,388$1,296
Institutional resident1,205,040$13,63821,880$11,813$1,825
Unknown9,146,200$7,559153,940$6,548$1,011
Chronic conditions    
Anemia5,212,220$11,14886,360$9,657$1,492
Rheumatoid arthritis7,987,660$10,244136,800$8,873$1,371
Asthma2,077,200$10,53442,740$9,125$1,410
Atrial fibrillation2,160,960$10,09624,240$8,745$1,351
Breast or prostate cancer1,581,540$12,27418,920$10,757$1,517
COPD2,767,340$10,10354,960$8,751$1,352
Congestive heart failure3,199,460$8,88451,220$7,695$1,189
Depressive disorders6,273,440$9,985139,940$8,787$1,198
Diabetes6,592,380$8,013136,920$6,941$1,072
Epilepsy594,560$9,40313,180$8,145$1,258
Hypothyroidism3,865,660$8,54057,540$7,398$1,143
Ischemic heart disease6,792,700$9,314107,780$8,068$1,246
Kidney disease4,279,460$9,41473,760$8,154$1,260
Liver disease790,800$11,63117,040$10,074$1,556
Mobility impairments577,820$12,76611,120$11,058$1,708
Obesity2,942,860$9,68769,620$8,503$1,184
Peripheral vascular disease2,888,480$9,21947,420$7,985$1,234
Pressure ulcers993,360$12,82716,060$11,110$1,716
Schizophrenia452,120$10,68613,840$9,256$1,430
Stroke/TIA907,500$11,93515,180$10,338$1,597
No. of chronic conditions    
04,513,760$1,68793,200$1,461$226
14,483,440$3,82382,120$3,311$512
24,105,140$5,69474,140$4,932$762
33,225,380$7,70159,420$6,670$1,030
42,357,580$9,84644,160$8,529$1,318
51,666,820$12,17329,760$10,544$1,629
61,164,460$14,43620,940$12,504$1,932
7801,800$16,22214,660$14,052$2,171
8544,880$18,12010,040$15,696$2,425
9357,240$19,1976,080$16,628$2,569
10 or more494,280$20,7258,720$17,952$2,773
NOTE: All values shown were risk adjusted using a model similar to the CMS HCC Risk Adjustment Model. Excludes beneficiaries in Puerto Rico and those who enrolled in cost, Medicare Medical Savings Account (MSA), PACE plans, Medicare-Medicaid Plans (MMPs) and employer group health plans. Excludes beneficiaries with end-stage renal disease. Excludes people who died before the end of 2015. Excludes people not enrolled in Medicare prior to 2013. TM is traditional Medicare. MA is Medicare Advantage. Only chronic conditions with at least 10,000 people switching to Medicare Advantage are shown in table.SOURCE: Kaiser Family Foundation analysis of the Chronic Conditions Data Warehouse 5% sample of claims, 2013-2016.
Table 2. Results from Multivariate Regression of Traditional Medicare Spending in 2015 for Beneficiaries who Switched to Medicare Advantage Or Stayed in Traditional Medicare in 2016, Adjusting for Risk Factors Included in the CMS HCC-Risk Adjustment Model
CoefficientsEstimateStd. Error
Intercept7.1096330.009402
Switching-0.1436510.0142682
Gender: Malereferent category
Female-0.01106860.0117174
Age 0-34-0.07129610.025248
35-44-0.01634060.021451
45-54-0.04088140.0170427
55-59-0.064270.0179617
60-64-0.01900080.017056
65-69 referent category
70-740.08736040.0095115
75-790.14112970.0101946
80-840.15774020.0112485
85-890.14946320.0130799
90-940.16662090.018159
95+0.31831930.0344025
Dual eligibility: Non-dualsreferent category
Partial duals-0.10387250.0282699
Full duals-0.13062160.0198355
Community residentsreferent category
Institutional residents0.41655340.0333449
Missing residency status-0.23924730.0071132
Original reason for entitlement: Agedreferent category
Disabled-0.00331690.0138178
Chronic conditions/HCC codes
Acute MI0.8105670.0252134
Anemia0.34125360.0120288
Asthma0.15156250.0151335
Atrial fibrillation0.12028880.0153342
Blindness0.19817320.0244406
Brain injury0.26452990.0313467
Breast or Prostate cancer0.27717320.0132984
Cerebral palsy-0.04894680.033602
Chronic kidney disease0.1549230.0152935
Colorectal cancer0.44364720.0204056
Congestive heart failure-0.04524620.05673
COPD0.23399840.0398189
Cystic fibrosis0.0347970.0282677
Depressive disorders0.09298280.0119425
Diabetes-0.16462570.0151394
Endometrial cancer0.44958530.0356021
Epilepsy 0.22263730.0456154
Hepatitis0.18176270.0225243
Hip/Pelvic fracture0.94090280.0247483
HIV/AIDS0.09274050.0346999
Hypothyroidism-0.12401660.0120557
Ischemic heart disease-0.01070280.0119693
Leukemia0.52177910.0189631
Liver disease0.23470110.0150768
Lung cancer0.63644710.0232583
Mobility impairments0.33943060.0170233
Multiple sclerosis0.43436220.0308529
Muscular dystrophy0.71382060.0798967
Obesity0.01734550.0123963
Peripheral vascular disease-0.02160040.0124903
Personality disorders0.17775240.02434
Pressure ulcers 0.4853860.0206655
PTSD0.04288330.0225038
Rheumatoid arthritis0.19571970.0116852
Schizophrenia0.12772050.0207238
Spina bifida 0.20695890.0493435
Spinal cord injuries0.49952320.0333971
Stroke/TIA0.27373270.0149603
No. of chronic conditions – 0referent category
10.81820020.0126207
21.216580.0228322
31.5185670.0335242
41.7643250.0443301
51.9764630.0551261
62.1469210.0659209
72.2636230.0766949
82.3742660.0874716
92.4319920.0983541
10 or more2.5085720.1192487
Interaction terms
Gender and age: 0-34 x female0.14512760.0377312
35-44 x female0.01140950.0303987
45-54 x female0.01550290.0239679
55-59 x female0.00304640.0253859
60-64 x female-0.02097320.0240343
70-74 x female-0.03466880.0130251
75-79 x female-0.06095980.0138234
80-84 x female-0.07284370.0150058
85-89 x female-0.0349320.0169001
90-94 x female0.00646020.0223403
95+ x female-0.06742940.0395159
Dual eligibility and institutional status: Full duals x institutional resident-0.11988340.0491795
Full duals x missing residency-0.03157020.0433176
Partial duals x institutional resident0.51075590.2224101
Partial duals x missing residency-0.55717220.0537358
Dual eligibility, institutional status, and original reason for entitlement: -0.11830590.0765971
Non-duals x institutional resident x disabled
Non-duals x missing residency x disabled-0.23365620.0162378
Full duals x community resident x disabled0.12275250.0263483
Full duals x institutional resident x disabled-0.16561440.0392149
Full duals x missing residency x disabled-0.31210910.0477308
Partial duals x community resident x disabled0.0594070.0349008
Partial duals x institutional resident x disabled-0.5222610.2330442
Partial duals x missing residency x disabled0.13591080.0591859
Dual eligibility, institutional status, original reason for entitlement, and gender:
Non-duals x institutional resident x aged x female-0.03601980.0387172
Non-duals x institutional resident x disabled x female0.06328130.0972535
Non-duals x missing residency x aged x female0.10229330.009524
Non-duals x missing residency x disabled x female0.20308380.0219463
Full duals x community resident x aged x female0.02536880.0238392
Full duals x community resident x disabled x female-0.01096530.0235554
Full duals x institutional resident x aged x female-0.07807930.036145
Full duals x institutional resident x disabled x female-0.01572710.0325536
Full duals x missing residency x aged x female0.2918270.0494258
Full duals x missing residency x disabled x female0.16342480.0433238
Partial duals x community resident x aged x female-0.06411330.0335277
Partial duals x community resident x disabled x female-0.01058620.028095
Partial duals x institutional resident x aged x female-0.375360.2447585
Partial duals x institutional resident x disabled x female-0.02017490.123955
Partial duals x missing residency x aged x female0.44194790.0623898
Partial duals x missing residency x disabled x female0.30765110.0604882
Original reason for entitlement, CHF:-0.10788230.0139239
Aged x CHF
Original reason for entitlement, Disabled x pressure ulcers:0.3214680.0158037
Original reason for entitlement, Aged x pressure ulcers0.4853860.0206655
Original reason for entitlement, Aged x multiple sclerosis:-0.2358610.0597826
Aged x multiple sclerosis
No Congestive heart failure x diabetes-0.31461910.0121283
Congestive heart failure x No diabetes0.16462570.0151394
No Congestive heart failure x (asthma or COPD or cystic fibrosis)-0.0390980.0152652
Congestive heart failure x No (asthma or COPD or cystic fibrosis)-0.00937650.0194537
No Congestive heart failure x chronic kidney disease-0.07775020.0128155
No Congestive heart failure x atrial fibrillation0.08526850.0142362
Congestive heart failure x No atrial fibrillation-0.12028880.0153342
Schizophrenia x congestive heart failure0.10683410.0439697
No Schizophrenia x COPD0.10299180.0169278
Schizophrenia x No COPD0.12772050.0207238
Schizophrenia x COPD0.36171880.0429217
Schizophrenia x epilepsy-0.13117770.0462925
NOTE: One dollar was added to all spending values to remove zeros. Other regressions included additional chronic conditions, county-level average traditional Medicare spending, and beneficiaries’ race/ethnicity with no meaningful change in results.SOURCE: Kaiser Family Foundation analysis of the Chronic Conditions Data Warehouse 5% sample of claims, 2013-2016.
Table 3. Average Traditional Medicare Spending in 2015, Unadjusted for Health Risk Factors, for Beneficiaries who Switched to Medicare Advantage Or Stayed in Traditional Medicare in 2016, In Selected Counties
County(Largest city in the county)People who stayed in TM in 2016People who switched to MA in 2016Difference in spending (unadjusted)Percentage difference in spending, 2015
Number of peopleAverage Part A & B spending, 2015Number of peopleAverage Part A & B spending, 2015
Allegheny, Pennsylvania (Pittsburgh)45,820$9,3581,440$11,464($2,105)-22%
Baltimore City, Maryland51,900$13,4131,140$14,831($1,418)-11%
Bexar, Texas (San Antonio)87,360$8,4271,720$7,957$4716%
Clark, Nevada (Las Vegas)104,260$9,3233,180$7,294$2,02922%
Cook, Illinois (Chicago)339,340$9,6296,040$6,653$2,97631%
Cuyahoga, Ohio (Cleveland)80,740$8,9412,160$5,312$3,62941%
Erie, New York (Buffalo)43,720$7,9921,300$9,489($1,498)-19%
Fulton, Georgia (Atlanta)39,480$7,9301,660$6,903$1,02713%
Harris, Texas (Houston)157,860$10,1345,040$7,725$2,40924%
King, Washington (Seattle)113,020$8,0442,820$6,029$2,01525%
Los Angeles, California322,160$11,7195,300$5,440$6,27854%
Marion, Indiana (Indianapolis)65,580$9,0842,720$9,597($513)-6%
Mecklenburg, North Carolina (Charlotte)53,760$7,8351,560$11,907($4,072)-52%
Miami Dade, Florida (Miami)87,920$12,5234,940$8,819$3,70430%
Milwaukee, Wisconsin51,820$9,2172,320$9,007$2102%
Multnomah, Oregon (Portland)25,800$9,2161,080$12,434($3,218)-35%
Queens, New York (New York City)102,980$11,4603,880$12,328($868)-8%
Salt Lake, Utah41,720$8,4181,220$6,296$2,12225%
San Bernardino, California46,720$9,5761,440$5,150$4,42646%
Wayne, Michigan (Detroit)125,520$11,2721,600$8,260$3,01227%
NOTE: Excludes beneficiaries in Puerto Rico and those who enrolled in cost, Medicare Medical Savings Account (MSA), PACE plans, Medicare-Medicaid Plans (MMPs) and employer group health plans. Excludes beneficiaries with end-stage renal disease. Excludes people who died before the end of 2015. Excludes people not enrolled in Medicare prior to 2013. TM is traditional Medicare. MA is Medicare Advantage.SOURCE: Kaiser Family Foundation analysis of the Chronic Conditions Data Warehouse 5% sample of claims, 2013-2016.
Table 4. Average Traditional Medicare Spending in 2015 for Beneficiaries who Switched to Medicare Advantage Or Stayed in Traditional Medicare in 2016, Unadjusted for Health Risk Factors
Characteristics in 2015People who stayed in TM in 2016People who switched to MA in 2016Difference in spendingPercentage difference in spending
Number of peopleAverage Part A & B spending, 2015Number of peopleAverage Part A & B spending, 2015
Overall23,714,780$8,859443,240$7,628$1,23114%
Age
Under 653,579,500$8,431131,680$8,461-$300%
65-693,360,240$6,90079,480$6,084$81512%
70-745,598,560$7,34196,280$5,915$1,42619%
75-794,341,380$8,79263,060$7,469$1,32315%
80 and older6,835,100$11,32772,740$10,347$9809%
Dual eligibility
Full dual eligible3,324,880$12,951100,360$12,310$6415%
Partial dual eligible1,257,160$9,22061,580$8,565$6547%
Non-dual eligible19,132,740$8,122281,300$5,788$2,33529%
Gender
Female13,211,740$9,071240,420$8,185$88710%
Male10,503,040$8,588202,820$7,017$1,57218%
Chronic conditions    
Anemia5,212,220$20,95886,360$20,026$9324%
Rheumatoid Arthritis7,987,660$14,133136,800$12,960$1,1738%
Asthma2,077,200$22,43842,740$19,451$2,98613%
Atrial fibrillation1,581,540$15,18118,920$13,531$1,65011%
Breast or prostate cancer2,160,960$20,35924,240$20,502-$143-1%
COPD3,199,460$23,28051,220$22,306$9754%
Congestive heart failure2,767,340$21,55154,960$18,925$2,62612%
Depressive disorders6,273,440$15,846139,940$13,779$2,06713%
Diabetes6,592,380$12,749136,920$10,973$1,77614%
Epilepsy4,279,460$19,83673,760$18,556$1,2816%
Hypothyroidism3,865,660$13,66857,540$12,931$7375%
Ischemic heart disease6,792,700$15,853107,780$15,162$6914%
Kidney Disease594,560$20,99313,180$18,447$2,54712%
Liver disease790,800$21,78917,040$19,090$2,69912%
Mobility impairments577,820$32,27911,120$29,137$3,14210%
Obesity2,942,860$16,43669,620$14,545$1,89212%
Peripheral vascular disease2,888,480$19,60647,420$18,489$1,1186%
Pressure ulcers452,120$15,31413,840$15,335-$210%
Schizophrenia993,360$31,39016,060$31,312$780%
Stroke/TIA907,500$26,58115,180$25,888$6943%
NOTE: Values have not been adjusted for differences in health status and other risk factors. Excludes beneficiaries in Puerto Rico and those who enrolled in cost, Medicare Medical Savings Account (MSA), PACE plans, Medicare-Medicaid Plans (MMPs) and employer group health plans. Excludes beneficiaries with end-stage renal disease. Excludes people who died before the end of 2015. Excludes people not enrolled in Medicare prior to 2013. TM is traditional Medicare. MA is Medicare Advantage. Only chronic conditions with at least 10,000 people switching to Medicare Advantage are shown in table.SOURCE: Kaiser Family Foundation analysis of the Chronic Conditions Data Warehouse 5% sample of claims, 2013-2016.

Endnotes

  1. Medicare Payment Advisory Commission, “Medicare Advantage encounter data,” Presentation to Commissioners, March 7, 2019. Available at: http://www.medpac.gov/docs/default-source/default-document-library/ma-encounter-data-march-2019.pdf ↩︎
  2. Neuman, Patricia and Gretchen Jacobson. “Medicare Advantage Checkup” New England Journal of Medicine 2018; 379: 2163-2172 Available at: https://www.nejm.org/doi/full/10.1056/NEJMhpr1804089 ↩︎
  3. Medicare Payment Advisory Commission, “Improving risk adjustment in the Medicare program,” June 2014. Available at: http://www.medpac.gov/docs/default-source/reports/jun14_ch02.pdf ↩︎
  4. Newhouse, Joseph P., J. Michael McWilliams, Mary Price, et al., “Do Medicare Advantage Plans Select Enrollees in Higher Margin Clinical Categories?” Journal of Health Economics. 2013 December; 32(6) ↩︎
  5. Newhouse, Joseph P., Mary Price, J. Michael McWilliams, et al., “How Much Favorable Selection is Left In Medicare Advantage?” American Journal of Health Economics. 2015 1(1):1-26 ↩︎
  6. McWilliams, J. Michael, John Hsu, and Joseph P. Newhouse, “New Risk-Adjustment System Was Associated With Reduced Favorable Selection In Medicare Advantage,” 2011. Vol. 31, no. 12. ↩︎
  7. We examined health care service utilization in 2015 among beneficiaries who switched to Medicare Advantage in 2016 vs. those who remained in traditional Medicare. As might be expected based on the finding of lower average spending, we found lower rates of utilization among those who switched to Medicare Advantage. The difference in percent of beneficiaries using services, was largest for Part B drugs, evaluation and management, imaging, tests, and physician visits, respectively. Among beneficiaries who used the specific services, the quantities used were not appreciably different. This analysis was conducted at the bivariate level. ↩︎
  8. Kaiser Family Foundation, “Medicare Advantage 2019 Spotlight: First Look,” October 2019. Available at: https://modern.kff.org/report-section/medicare-advantage-2019-spotlight-first-look-tables/ ↩︎
  9. Raetzman, Susan O., Anika L. Hines, Marguerite L. Barrett, and Zeynal Karaca, “Hospital Stays in Medicare Advantage Plans Versus the Traditional Fee-for-Service Program, 2013,” HCUP Statistical Brief #198. December 2015. Agency for Healthcare Research and Quality, Rockville, MD. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb198-Hospital-Stays-Medicare-Advantage-Versus-Traditional-Medicare.pdf. ↩︎
  10. Landon, Bruce E., Alan M. Zaslavsky, Robert C. Saunders, et al., “Utilization of Services in Medicare Advantage versus Traditional Medicare since the Passage of the Medicare Modernization Act,” Health Affairs. 2012; 31(12): 2609-2617. ↩︎
  11. Ayanian, John Z., Landon, Bruce E., Newhouse, Joseph P. et. al. “Analysis of Medicare Advantage HMOs Compared with Traditional Medicare Shows Lower Use of Many Services During 2003-09.” Health Affairs, 31, 12 (December 2012): 1-9. ↩︎
  12. A recent study found that death rates were initially lower among beneficiaries who enrolled in Medicare Advantage than those who stayed in traditional Medicare but the rates began to converge over time, raising questions about the differences in case mix between traditional Medicare and Medicare Advantage, and how potential overpayments would change over time. See Newhouse, Joseph P., Mary Price, J. Michael McWilliams, et al., “Adjusted Mortality Rates Are Lower For Medicare Advantage Than Traditional Medicare, But The Rates Converge Over Time,” Health Affairs, 38, 4 (April 2019). ↩︎
  13. Congressional Budget Office, “Medicare Baseline,” April 2018. Available at: https://www.cbo.gov/system/files?file=2018-06/51302-2018-04-medicare.pdf ↩︎
  14. Kaiser Family Foundation, “A Dozen Facts About Medicare Advantage,” November 2018. Available at: https://modern.kff.org/medicare/issue-brief/a-dozen-facts-about-medicare-advantage/ ↩︎
News Release

Poll Finds Most Americans Oppose the Trump Administration’s Changes to Restrict Title X Family Planning Funds from Clinics that also Provide or Refer for Abortion

Few Want Funds to Go to Clinics that Only Promote Abstinence or Natural Family Planning Without Providing Contraception

Published: May 3, 2019

A new KFF poll of the public’s views on reproductive health issues finds most Americans, including majorities of women of reproductive age, are concerned that access to women’s reproductive health and preventive care services may be limited by the Trump administration’s changes to Title X, the nation’s federal family planning program. The poll examines the public’s views of major regulatory changes to the Title X program, which funds nearly 4,000 clinics nationally to pay for family planning and other preventive services to lower-income women. Originally set to take effect today but blocked by national injunctions issued by multiple federal judges, the new regulations would prohibit federal funding to any family planning clinic that also provides abortion services or referrals, even though none of the funds could be used for abortions. Most of the public (58%) oppose changing the program to exclude organizations that provide abortions or referrals for abortions with other resources, while nearly four in 10 (38%) favor such changes. Most Democrats (68%) and independents (57%) oppose such changes, though Republicans are divided (47% favoring, 48% opposing).

Poll Finds Most Americans Oppose the Trump Administration’s Changes to Restrict Title X Family Planning Funds from Clinics that also Provide or Refer for Abortion

The new regulation could also channel federal family planning funds to “non-traditional” organizations that only offer natural family planning methods or promote abstinence and do not provide other contraceptive services. Most of the public – including at least half of Republicans – oppose allowing federal family planning funds to go to organizations that either only counsel about natural family planning methods (68%); don’t counsel pregnant women and girls about all of their options including prenatal care, adoption and abortion (65%); or do not provide contraception or birth control (59%). Most women, including most women of reproductive age, oppose funding such organizations. KFF polling has consistently found strong support for federal funding for reproductive health services for lower-income women with majorities of Democrats, independents, and Republicans saying it is important the government provide this funding. This month’s poll also finds, in light of the Trump administration’s actions, 68% of Americans, including three-fourths (76%) of women of reproductive age and nearly half of Republicans (49%), say they are “very” or “somewhat” concerned that the new regulations would limit access to women’s reproductive health and preventive care services.

If implemented, the new regulations would prohibit Title X funds from going to Planned Parenthood, the nation’s largest family planning provider and biggest Title X grant recipient. Some states have also proposed cutting off funding to Planned Parenthood for any services. When asked about such changes, about seven in 10 (69%) Americans say their state should continue to make payments to Planned Parenthood, while about three in 10 (29%) say their state should stop payments. Views split along partisan lines, with a large majority of Democrats (86%) wanting Planned Parenthood payments to continue and most Republicans (57%) wanting such payments to stop. Public Split on Fetal Heartbeat Bills that Ban Abortions Early in Pregnancy The poll also assesses the public’s views on other issues related to reproductive health and abortion, including some states’ efforts to enact new abortion restrictions that could lead the Supreme Court to revisit the 1973 Roe v. Wade decision that established a women’s constitutional right to an abortion. These include “fetal heartbeat” bills, enacted in Ohio and under consideration in other states, that prohibit a woman from having an abortion once a fetal heartbeat is detected. The public initially splits on whether their state should enact a fetal heartbeat ban, with half supporting it and nearly as many (44%) opposing it. Republican women are most supportive of such a ban, with about three quarters (77%) favoring it. However, when supporters are informed that a fetal heartbeat can be detected around six weeks into pregnancy, before most women know they are pregnant, enough switch their views to create a more narrow majority (56%) opposing a fetal heartbeat ban. Overall, two-thirds of the public (65%) do not want to see the Supreme Court overturn Roe v. Wade, while about one-third (32%) would like to see the decision overturned. These views split along partisan lines, with most Republicans (56%) wanting to see it overturned and larger majorities of Democrats (80%) and independents (68%) wanting it to stand. If Roe v. Wade were to be overturned, 42% of the public believes that abortion would no longer be legal in their state while half believe it would still be legal in their state. Public Unaware of Some ACA Provisions Affecting Women’s Health Services and Coverage The poll also examines the public’s knowledge about key provisions of the 2010 Affordable Care Act that relate to the availability of reproductive health care services. While most (62%) know that the ACA requires insurance plans to include a minimum package of benefits including maternity care, fewer know that the law eliminates out-of-pocket costs for many preventive services including mammograms (48%); eliminates out-of-pocket costs for birth control (38%), and prohibits insurers from charging women more than men for their health coverage (36%). Partisans Split on Trump Administration Policy that Blocks U.S. Foreign Aid to Foreign Organizations that Perform or Promote Abortion, Even if They Use Their Own Funds to Do So The poll also examines the public’s views of the Mexico City Policy, which every Republican administration since President Reagan has adopted to prevent U.S. global family planning funding from going to foreign organizations that perform or promote abortion as a method of family planning, even using their own funds. The Trump administration has expanded the policy to apply to almost all U.S. global health funding. While the majority of the public does not support this restriction, as with other abortion-related issues, views of the Mexico City Policy diverge along partisan lines. When asked about the expanded policy, most (55%) oppose the restrictions, including a large majority of Democrats (73%) and a smaller majority of independents (53%). In contrast, nearly two-thirds (64%) of Republicans support the expanded restrictions. Designed and analyzed by public opinion researchers at KFF, the poll was conducted April 23-28, 2019 among a nationally representative random digit dial telephone sample of 1,200 adults. Interviews were conducted in English and Spanish by landline (305) and cell phone (895). The margin of sampling error is plus or minus 3 percentage points for the full sample and 9 percentage points for women ages 18-44. For results based on subgroups, the margin of sampling error may be higher.

Poll Finding

KFF Poll: Public Opinion and Knowledge on Reproductive Health Policy

Published: May 3, 2019

Findings

Kaiser Family Foundation has a long record of measuring the public’s attitudes on reproductive health care issues, including several in-depth surveys of women of reproductive age (between the ages of 18 and 44). In this poll, KFF examines public opinion towards many different facets of reproductive health care, with a focus on recent changes to federal reproductive health policy made by the Trump administration. In particular, the administration recently finalized major changes to the Title X program, which provides federal funding for family planning services for lower-income people. If implemented, these changes would prohibit federal Title X funds from going to any family planning organization that also provides abortion services or referrals.  The new regulation could also channel federal family planning funds to “non-traditional” organizations that only offer natural family planning methods or promote abstinence and do not provide other contraceptive services. The implementation of the new rule was recently halted by court order, but litigation continues. The Trump administration also recently expanded the Mexico City Policy, which restricts federal funding to organizations abroad if they provide abortion services or counseling or referrals for abortions.

This poll also examines public attitudes toward laws that have been recently passed by a number of states prohibiting abortions after a fetal heartbeat has been detected and before many women even know they are pregnant. The poll continues KFF’s tracking of the public’s awareness of provisions related to women’s health that are part of the 2010 Affordable Care Act (ACA).

Key Findings:

  • The poll continues to find strong support for federal government funding for reproductive health services for lower-income women, known as Title X funding. Majorities of Democrats and independents think it is important that the federal government provides this funding for lower-income women to access reproductive health services, as do a majority of Republican women (62 percent).
  • Earlier this year, the Trump administration made major changes to federal rules regarding the Title X family planning program. The final rule included several changes, most notably blocking federal funding from any family planning provider that either offers or refers abortions to pregnant people – even though the federal funds do not pay for abortions. On these changes, public opinion largely falls along party lines with most Democrats and independents opposing these changes. Republicans are divided with similar shares supporting the Trump administration’s changes as opposing them. The rules have been challenged by numerous family planning organizations, providers, and state attorneys general and are currently temporarily blocked by court orders.1 

    68% of Americans say they are concerned new #TitleX family planning regulations would limit access to women’s reproductive health and preventive care services.

  • Most Americans – including three-fourths of women ages 18-44 – say they are concerned (either “very” or “somewhat”) that access to women’s reproductive health and preventive care services may be limited by the new rules that don’t allow clinics that provide abortions or refer for abortions to receive federal funding.
  • The poll finds agreement across party lines on the issue of federal funding to groups that promote abstinence-only or natural family planning methods. At least half of Democrats, independents, and Republicans say they oppose federal funding going to organizations that do not provide a full array of contraceptive services. Majorities – across party identification – also oppose allowing federal funding to go to organizations that promote abstinence as the only option and do not teach young people about contraception and STD prevention.
  • The poll also gauges awareness and attitudes towards restrictions on U.S. funding for foreign non-governmental organizations that provide abortions or counsel or refer for abortions, using their own funds, known as the Mexico City Policy. While the majority of the public does not support such restrictions, views diverge along partisan lines, with most Democrats and independents opposing them and most Republicans supporting the actions by the Trump administration.
  • In addition to the recent Trump administration’s actions on reproductive health care, there have also been state-level activities – including passing laws banning abortions after a fetal heartbeat can be detected (normally six weeks into a pregnancy). Opinions towards this type of legislation are largely partisan with Democrats (65 percent) opposing their state passing a similar ban and Republicans supporting it (70 percent) – including three-fourths of Republican women.
  • The implementation of the Affordable Care Act (ACA) had major implications for women’s health, but this survey finds there is still confusion about what the 2010 health care law actually does in terms of women’s health care. Less than half of the public are aware the ACA eliminates out-of-pocket costs for birth control (38 percent) and prohibits insurance companies from charging women more than men (36 percent).

Trump Administration and Reproductive Health Care

The Trump administration has pursued a far-reaching strategy aimed at changing the federal government’s position on domestic and international reproductive health policy. On February 22, 2019, the Department of Health and Human Services released the final rule regarding use of Title X federal funds for family planning clinics. These regulations affect nearly 4,000 clinics, which provide health care services to lower-income women in all 50 states.

Partisans Hold Differing Views towards Federal Funding Going to Organizations that Provide Both Contraception and Abortion Services

The Title X program funds clinics across the country to provide family planning services to lower-income women. The program has always prohibited federal funding to be used for abortions; but the new regulations expand these restrictions so that funding cannot go to any organizations that provide contraceptive services if they also provide abortions or refer for abortions. Majorities of the public oppose changing the regulations to exclude any organization that provides abortions (60 percent) or referrals for abortions (56 percent).

Figure 1: Majorities Oppose Restricting Federal Funding From Clinics Providing Both Contraceptive And Abortion Services

These attitudes are largely partisan with about seven in ten Democrats (68 percent) opposing the restrictions on federal funding to organizations that either provide abortions or referrals for abortions while Republicans are divided with similar shares saying they support (47 percent) and oppose (48 percent) the new rule. A larger share of independents say they oppose the new rule (57 percent) than say they support it (40 percent).

Figure 2: Democrats And Independents Don’t Want Restrictions On Clinics That Provide Both Contraceptive And Abortion Services

Public Perceptions of the Implications of Title X Rule

Overall, seven in ten (including 87 percent of Democrats, two-thirds of independents, and nearly half of Republicans) are concerned (either “very” or “somewhat”) that access to women’s reproductive health and preventive care services may be limited by the new rules that don’t allow family planning clinics that also provide abortions or refer for abortions to receive federal funding. In addition, three-fourths of women ages 18-44 (76 percent) say they are concerned that access to reproductive health and preventive care services may be limited by the new rules.

Figure 3: Seven In Ten Are Concerned About Access To Women’s Health Services Under New Rules For Title X Program

In addition, KFF continues to find strong support for federal government funding for reproductive health services for lower-income women. Three-fourths of the public say it is important (either “very” or “somewhat” that the federal government provides funding for reproductive health services including family planning and birth control for lower-income women. While a large majority of Democrats (83 percent) and six in ten independents say this is “very” important, the share is much smaller among Republicans (29 percent). This is consistent with previous KFF polling which found majorities of both women and men reporting that it is important that this funding continues.

Figure 4: Majorities Say It Is Important To Provide Funding For Reproductive Health Services For Lower-Income Women

A majority of women (85 percent) say it is important the federal government provides this funding including seven in ten who say it is “very important.” Support is consistent across women with majorities of women, regardless of party identification, age, and income, saying this funding is at least somewhat important.

Figure 5: Majorities Of Women Say It Is Important That The Government Fund Reproductive Health Services For Lower-Income Women

Republican Women

While Republican women’s support for the Trump administration’s actions limiting federal funding from going to family planning clinics that provide abortions or referrals for abortions is similar to the support of Republican men. Republican women are more likely than their male counterparts to generally support Title X funding for reproductive health care for lower-income women. Six in ten Republican women (62 percent) say it is either “very important” or “somewhat important” the federal government provides funding for reproductive health services for lower-income women (compared to 96 percent of Democratic women, 85 percent of independent women, and 47 percent of Republican men). In addition, they are divided on whether these actions will limit access to women’s reproductive health and preventive care services. Slightly more than half (53 percent) say they are concerned that access will be limited by these new rules compared to 46 percent who say they are not concerned.

Most Oppose Allowing Federal Funding To Go To Groups That Promote Natural Family Planning or Abstinence-Only

While views towards the new rules prohibiting Title X funds from going to organizations that provide both contraceptive and abortion services are largely partisan, there is some consensus across political parties towards other changes to the Title X program.

One of the major changes in the Trump administration’s final Title X rule is removing the requirement that organizations that receive federal Title X funding must provide counseling to pregnant women that “includes abortion, adoption, and prenatal care referrals.” The new Title X regulation permits and encourages the participation of “non-traditional” organizations that only offer natural family planning (NFP) (such as fertility awareness or the rhythm method), or promote abstinence, and do not necessarily provide contraceptive services.

A majority of the public – including a majority of women – oppose these changes to the federal funding structure. About seven in ten (68 percent) oppose allowing federal funding to go to organizations that only provide counseling on NFP methods, such as the rhythm method. Two-thirds oppose (65 percent) allowing federal funding to go to organizations that do not counsel pregnant people about all of their choices, including prenatal care, adoption, and abortion; and about six in ten (59 percent) oppose federal family planning funding to support organizations that do not provide contraception or birth control.

Figure 6: Majorities Oppose Changes Allowing Federal Funding To Go To Organizations That Provide Limited Reproductive Services

At least half of Democrats, independents, and Republicans say they oppose federal funding to go to organizations that do not provide a full array of reproductive health care services.

Figure 7: Across Partisans, Most Oppose Changes Allowing Title X Funding To Go To Groups Providing Limited Reproductive Services

A majority of women ages 18-44 oppose allowing federal funding to go to organizations that only provide counseling on natural family planning methods (73 percent), do not counsel pregnant people about all of their choices including prenatal care, adoption and abortion (66 percent), or do not provide contraception or birth control (64 percent).

Similarly, the public largely opposes federal funding for abstinence-only education for teenagers. The Trump administration recently announced new guidelines for funding programs to prevent teenage pregnancy. These new guidelines promote organizations that teach abstinence-only or emphasize “sexual risk avoidance.”

About seven in ten adults (72 percent) oppose allowing federal funding to go to organizations that promote abstinence as the only option and do not teach young people about contraception and STD prevention. Majorities of Democrats (77 percent) and independents (75 percent) oppose, as do a majority of Republicans (59 percent).

Figure 8: Majorities Oppose Allowing Federal Funding To Go To Organizations That Only Promote Abstinence

More generally, about six in ten Americans (63 percent) think teenagers should be able to get confidential health services such as STD tests, birth control, or pregnancy tests without their parent’s involvement and 61 percent say this is either “very important” or “somewhat important.” A majority of Democrats (78 percent) and independents (62 percent) and fewer Republicans (39 percent) think it is important for teenagers to be able to access these types of health services without parental involvement.

Figure 9: Six In Ten Think It Is Important For Teenagers To Get Confidential Health Services Without Parental Involvement

Mexico City Policy

While U.S. law (the Helms Amendment) restricts the use of foreign aid from paying for abortions, in early 2017, the Trump administration reinstated the Mexico City Policy, which further restricts the use of U.S. funding. Specifically, it restricts U.S. funding from going to foreign non-governmental organizations that “perform or actively promote abortion as a method of family planning” using their own money; this includes providing abortions as well as counseling and referrals for abortions. The policy, first announced by President Reagan, has been rescinded and reinstated by subsequent administrations – depending on the President’s political party. Previously, when in place under prior Republican administrations, the Mexico City Policy had only applied to foreign organizations receiving U.S. global family planning funding. The Trump administration expanded it to nearly all U.S. global health funding, greatly increasing its scope.

Overall, most (60 percent) of the public are aware that U.S. government funding to foreign groups that provide reproductive health care and family planning services cannot be used to pay for abortions although about one-fourth (26 percent) incorrectly believe it can be used to pay for abortions.

Figure 10: Most Are Aware U.S. Funding Cannot Be Used To Pay For Abortions In Other Countries

When asked whether they support or oppose the federal government expanding these restrictions so that no U.S. funding can go to foreign groups that provide abortions or counseling or referrals for abortions, even with their own funding, a larger share of the public oppose this expansion of U.S. policy than support it. More than half oppose expanding these restrictions so that U.S. funding cannot go to foreign groups that provide abortions (56 percent) or referrals for abortions (54 percent) even with their own funds. More than half of women oppose these restrictions while men are more divided.

Figure 11: Majorities Oppose Expanding Restrictions On U.S. Funding To Foreign Groups

Similar to views of domestic spending, views of international policy in this area fall along largely partisan lines. Majorities of Democrats oppose expanding restrictions on U.S. funding to any foreign group that provides ether abortions or counseling or referrals for abortions (73 percent), while most Republicans support these restrictions (64 percent). Independents are more divided with 53 percent opposing the federal government expanding these restrictions and 42 percent supporting.

Figure 12: Majority Oppose Expanding Restrictions On Federal Funding To Foreign Groups, But Views Fall Along Largely Party Lines

Planned Parenthood

The Trump administration’s new final rule would also mean that Title X funding to Planned Parenthood, the nation’s largest family planning providers, would be blocked.2  In addition to Title X funding, Planned Parenthood clinics participate in the Medicaid program, which reimburses them for family planning services they provide to millions of lower-income people across the U.S. Nearly four in ten (38 percent) women report having ever visited a Planned Parenthood clinic.

While no federal funding to Planned Parenthood is used to pay for abortions, some states have proposed stopping all payments to Planned Parenthood for any family planning services, such as contraception or STI testing. Seven in ten (69 percent) would like their state to continue making payments to Planned Parenthood while about three in ten (29 percent) say all state payments to Planned Parenthood should be stopped. Views towards state payments to Planned Parenthood are largely partisan with nearly nine in ten Democrats (86 percent) and three-fourths of independents (74 percent) wanting to see state payments continue, while nearly six in ten Republicans (57 percent) want state payments to stop. Sizable majorities of women, overall (76 percent), and those 18-44 years old (87 percent) also support continuing state payments to Planned Parenthood. Republican women are divided with similar shares saying their state should stop payments (50 percent) as say the payment should continue (48 percent).

Figure 13: Most Say Payments To Planned Parenthood Should Continue, Republicans Say Payments Should Be Stopped

Attitudes towards continued state payments to Planned Parenthood seem somewhat malleable with about one-tenth of the public, on either side of the argument, changing their minds after hearing counter-arguments. For example, one-fourth (7 percent overall) change their minds and now want to see the state payments to Planned Parenthood continue after hearing that this change would make it difficult for many lower-income women to access certain health services. This brings the total share who want to see their state payments to Planned Parenthood continue up to three-fourths of the public (76 percent). On the other side of the argument, 12 percent (8 percent of overall) change their minds after hearing that while the funding does not go directly to abortions, the organization does provide or refer for abortion (bringing the share who want to see state payments stop up to 37 percent).

Figure 14: Some Attitudes Towards Payments To Planned Parenthood Shift After Hearing Counter-Arguments

Challenges to Roe v. Wade

In addition to the Trump administration’s actions, there have been other state-level challenges to reproductive health care access.3  For example, Ohio lawmakers recently banned abortions after a fetal heartbeat can be detected. There are similar laws in 14 other states.4 

When asked about their own state passing a similar “heartbeat” ban, the public is divided with a slightly larger share supporting such a law (50 percent) while 44 percent are opposed. There are stark partisan differences with seven in ten Republicans saying they support their state passing a ban on abortions once a fetal heartbeat is detected while nearly two-thirds of Democrats (65 percent) are opposed. Independents are more divided with similar shares supporting (53 percent) and opposing (44 percent) a ban. Among women ages 18-44, about half (52 percent) oppose their state passing a law restricting abortions once a fetal heartbeat is detected while 42 percent support passing this type of law.

Figure 15: Half Support Their State Passing Laws Banning Abortions Once A Fetal Heartbeat Is Detected

While generally Republicans are more supportive of their state passing similar legislation, Republican women are more supportive than any other group. Three-fourths (77 percent) of Republican women support their state passing a ban on abortions once a fetal heartbeat is detected, compared to 64 percent of Republican men.

Table 1: Republican Women Are The Group Most Supportive Of Fetal Heartbeat Bills
Some states have passed laws that ban abortions once a fetal heartbeat is detected. Do you support or oppose your state passing a ban on abortions once a fetal heartbeat is detected?SupportOpposeDon’t know/ Refused
DemocratsWomen25%65%10%
Men31654
IndependentsWomen53443
Men52453
Republicans Women77167
Men64315

Opponents argue that restricting abortions once a fetal heartbeat is detectable may effectively ban abortions six weeks into pregnancy and before many women know they are pregnant. About one-fourth of those who support a ban (12 percent of total) change their minds after hearing that this ban would restrict abortions before many women know they are pregnant – bringing total opposition up to 56 percent overall.

Figure 16: More Oppose State Abortion Ban After Hearing Fetal Heartbeat Is Detected Before Many Women Know They Are Pregnant

With multiple states passing bills aimed at restricting access to abortions, many legal scholars believe that the U.S. Supreme Court will be forced to take up one of these cases, thereby forcing the Court to revisit Roe v. Wade, the 1973 U.S. Supreme Court case which established a woman’s constitutional right to have an abortion. Overall, two-thirds of the public (65 percent) do not want to see the Supreme Court overturn Roe v. Wade, while about one-third (32 percent) would like to see the decision overturned.

Unsurprisingly, attitudes are largely partisan with a majority (56 percent) of Republicans wanting to see Roe v. Wade overturned, while eight in ten Democrats and about seven in ten independents (68 percent) do not want the decision overturned. Two-thirds of women overall and seven in ten women ages 18-44 say they would like to see Roe v. Wade stay in place.

Figure 17: Majority Of The Public Does Not Want Supreme Court To Overturn Roe v. Wade

If the U.S. Supreme Court overturns Roe v. Wade, it would leave the legality of abortion up to individual states5 . In recent years, a number of states including Arkansas, Louisiana, North Dakota, South Dakota, and Mississippi have passed “trigger laws” which would make abortion illegal in the state if the Roe v. Wade decision is overturned. Overall, half of adults (50 percent) think abortion would continue to be legal in their state, while 42 percent think it would no longer be legal. And notably, 63 percent of those who live in states that have passed or have introduced legislation that would enact a “trigger law” think abortion would not be legal in their state if the Supreme Court overturned Roe v. Wade. Conversely, 59 percent of Americans in states which have no proposed “trigger laws” think abortion would remain legal in their states should the Supreme Court overturn the decision.6 

Figure 18: Half Of Public Believe Abortion Would Continue To Be Legal In Their State If Roe v. Wade Were Overturned

Public Still Largely Unaware Of Key ACA Reproductive Health Care Provisions

The implementation of the Affordable Care Act (ACA) had major implications for women’s health and access to care with requirements such as mandatory maternity care, coverage without cost-sharing for preventive services such as contraception, and a prohibition on gender rating – charging women more than men for the same coverage.7  While some changes took several years to implement, many of these requirements were implemented more than nine years ago. The poll finds there is still some confusion of what the 2010 health care law actually does. Six in ten (62 percent) are aware the law requires insurance plans purchased by individuals to include a minimum package of benefits including maternity care while about half (48 percent) are aware the law prohibits insurance companies from denying coverage based on a person’s medical history or that the law eliminates out-of-pocket costs for preventive health care services (48 percent). Less than half are aware the ACA eliminates out-of-pocket costs for birth control (38 percent) and prohibits insurance companies from charging women higher premiums than men (36 percent).

Figure 19: Large Shares Of The Public Are Unaware Of Some Of The ACA’s Reproductive Health Provisions

Overall, a larger share of women than men are aware of most of these provisions. For example, 45 percent of women overall are aware the ACA eliminated out-of-pockets for birth control (including 54 percent of women 18-44 years old) compared to three in ten men.

Table 2: Women Are More Knowledgeable Than Men About ACA Provisions Affecting Reproductive Health Care
Percent who are aware the ACA does each of the following:MenWomenWomen, 18-44
Requires health plans to include a minimum package of benefits set by the federal government59%66%65%
Prohibits insurance companies from denying coverage because of pre-existing conditions435348
Eliminates out-of-pocket costs for many preventive services, including mammograms and cholesterol screenings405562
Prohibits insurance companies from charging women higher premiums than men314136
Eliminates out-of-pocket costs for birth control304554

At the same time, misconceptions about the law remain. About one-third (33 percent) of the public incorrectly believe the ACA requires health insurance plans to cover abortions including 36 percent of men and about three in ten women overall and between the ages of 18 and 44 (29 percent). The misconception is more common among Republicans (41 percent). The ACA actually allows states to ban the sale of plans that offer abortion coverage through their ACA marketplaces and has special rules to separate the costs of abortion coverage for plans in states that still permit abortion coverage.

Figure 20: About One-Third Have Misconceptions About ACA’s Requirements Around Abortion Coverage

Methodology

This KFF Poll: Public Opinion and Knowledge on Reproductive Health Policy was designed and analyzed by public opinion researchers at the Kaiser Family Foundation (KFF). The survey was conducted April 23rd -28th 2019, among a nationally representative random digit dial telephone sample of 1,200 adults ages 18 and older, living in the United States, including Alaska and Hawaii (note: persons without a telephone could not be included in the random selection process). The sample included 253 respondents reached by calling back respondents that had previously completed an interview on the KFF Tracking poll more than nine months ago. Computer-assisted telephone interviews conducted by landline (305) and cell phone (895, including 643 who had no landline telephone) were carried out in English and Spanish by SSRS of Glen Mills, PA. To efficiently obtain a sample of lower-income and non-White respondents, the sample also included an oversample of prepaid (pay-as-you-go) telephone numbers (25% of the cell phone sample consisted of prepaid numbers) as well as a subsample of respondents who had previously completed Spanish language interviews on the SSRS Omnibus poll (n=10). Both the random digit dial landline and cell phone samples were provided by Marketing Systems Group (MSG). For the landline sample, respondents were selected by asking for the youngest adult male or female currently at home based on a random rotation. If no one of that gender was available, interviewers asked to speak with the youngest adult of the opposite gender. For the cell phone sample, interviews were conducted with the adult who answered the phone. KFF paid for all costs associated with the survey.

The combined landline and cell phone sample was weighted to balance the sample demographics to match estimates for the national population using data from the Census Bureau’s 2017 American Community Survey (ACS) on sex, age, education, race, Hispanic origin, and region along with data from the 2010 Census on population density. The sample was also weighted to match current patterns of telephone use using data from the January-June 2018 National Health Interview Survey. The weight takes into account the fact that respondents with both a landline and cell phone have a higher probability of selection in the combined sample and also adjusts for the household size for the landline sample, and design modifications, namely, the oversampling of prepaid cell phones and likelihood of non-response for the re-contacted sample. All statistical tests of significance account for the effect of weighting.

The margin of sampling error including the design effect for the full sample is plus or minus 3 percentage points. Numbers of respondents and margins of sampling error for key subgroups are shown in the table below. For results based on other subgroups, the margin of sampling error may be higher. Sample sizes and margins of sampling error for other subgroups are available by request. Note that sampling error is only one of many potential sources of error in this or any other public opinion poll. Kaiser Family Foundation public opinion and survey research is a charter member of the Transparency Initiative of the American Association for Public Opinion Research.

GroupN (unweighted)M.O.S.E.
Total1,200±3 percentage points
Women526±5 percentage points
Women, 18-44141±9 percentage points
Men671±4 percentage points
Party Identification
Democrats365±6 percentage points
Republicans345±6 percentage points
Independents357±6 percentage points
Half-sample A634±5 percentage points
Half-sample B566±5 percentage points
Survey subgroup C632±5 percentage points
Survey subgroup D595±5 percentage points

Endnotes

  1. P. Belluck. “Judge Temporarily Blocks Trump Rule on Abortion Referrals. The New York Times. April 25, 2019. Available at https://www.nytimes.com/2019/04/25/science/title-x-injunction-abortion-referrals.html ↩︎
  2. Planned Parenthood clinics serve about 40 percent of the 4 million patients who receive care in clinics that receive Title X funding each year. https://kffhealthnews.org/news/hhs-finalizes-rule-seeking-to-expel-planned-parenthood-from-family-planning-program/ ↩︎
  3. According to a report released by Planned Parenthood Federation of American and Guttmacher Institute. Full report available at https://www.plannedparenthood.org/uploads/filer_public/71/bc/71bc6e9b-dff8-4201-8ed3-141df7dce0e2/190325-media-state-abortion-bans-snapshot-v6.pdf ↩︎
  4. B. Farmer and J. Fortier. “Heartbeat Bills Give State Lawmakers Pause on Anti-Abortion Tactics.” Kaiser Health News. April 16, 2019. Available at https://kffhealthnews.org/news/heartbeat-bills-give-state-lawmakers-pause-on-anti-abortion-tactics/ ↩︎
  5. J. Rovner. “If High Court Reverses Roe V. Wade, 22 States Poised To Ban Abortion.” Kaiser Health News. July 10, 2018. Available at https://kffhealthnews.org/news/if-high-court-reverses-roe-v-wade-22-states-are-likely-to-ban-abortion/ ↩︎
  6. States with enacted trigger laws: Arkansas, Kentucky, Louisiana, Mississippi, South Dakota, North Dakota; states with proposed trigger laws: Georgia, Tennessee, Oklahoma, South Carolina, Missouri, Indiana, Texas, Washington. ↩︎
  7. Previous KFF polling has found that large majorities of the public say it is important for the ACA’s requirements affecting women be kept in place.   ↩︎
News Release

New KFF/Los Angeles Times Survey Highlights the Financial Challenges Facing People with Employer Health Benefits

While Most are Satisfied with Their Coverage, Those with High Deductibles or Chronic Health Conditions Often Struggle with Costs

Published: May 2, 2019

A new KFF/Los Angeles Times survey of Americans with employer health benefits finds that although most are largely satisfied with their employer plan, many report financial challenges related to their health care costs, particularly among those facing high deductibles or suffering from chronic health conditions.

The survey captures the experiences of the roughly 156 million Americans who get their health coverage through their employers, rather than through the individual market or government programs such as Medicare and Medicaid.

Overall 40% of those with employer coverage report problems paying medical bills or difficulty affording their premiums, deductibles, cost sharing or an unexpected bill in the past year. Half (51%) say they or someone in their family have skipped or postponed needed care or medication or relied on home remedies instead of seeking care because of the cost.

These problems occur more frequently as a plan’s annual deductible rises, with the greatest challenges occurring among the one in five (21%) Americans with employer coverage who face the highest deductibles – at least $3,000 for an individual or at least $5,000 for a family.

Similar challenges face the roughly half (54%) of people with employer coverage who say someone in their family is being treated for a chronic condition such as diabetes, heart disease, cancer, high blood pressure, asthma or a serious mental illness. For example:

  • About half of those with the highest deductibles and of those with chronic health conditions (49% of each group) had difficulty affording health care or insurance costs in the past year.
  • Most of those with the highest deductibles (62%) or chronic health conditions (60%) say they or a family member skipped or postponed care or medication in the past year because of cost.
  • More than half (56%) of those with the highest deductibles say they do not have readily available savings to cover their deductible.
  • People whose family includes someone with a chronic health condition are more than twice as likely as others with employer coverage to have made various financial sacrifices to pay their health care or insurance costs, such as increasing credit card debt (28% v. 12%), using up all or most of their savings (26% v. 11%) or taking on an extra job or working more hours (19% v. 8%).

The survey also probes the experiences of people with plans tied to tax-preferred Health Savings Accounts (HSAs), how people with employer coverage make health insurance decisions, and their perceptions about the health care system. The Los Angeles Times is featuring findings in a series of articles on high deductible plans. A KFF report provides the full detailed findings.

Overall most people are happy with their employer coverage, with nearly seven in 10 (68%) giving their plan an “A” or “B” grade. Similar shares say they are grateful (72%) and content (69%) with their plan, while far fewer say they feel frustrated (26%), confused (23%) or angry (14%). Views are more negative among those with the highest deductibles.

The survey finds a big shift since 2003 in the importance of low costs for people with employer coverage. When asked about the most important feature in a health plan, six in 10 (59%) cite cost-related features such as low premiums, deductibles or cost sharing, while a quarter (26%) cite coverage concerns such as a wide range of benefits or a wide choice of doctors or hospitals. Those priorities are roughly the mirror image of the results of 2003 KFF survey, in which 60% cited coverage issues and 33% citing cost-related features.

Other findings include:

  • Fewer than a third (31%) of those with high deductible plans linked to a HSA report having at least $2,000 in their accounts. Two-thirds (68%) say they view their HSA mostly as a way to pay for current medical bills, compared to a third (32%) who see it as a way to save for the future.
  • When asked about tradeoffs people would be willing to make in exchange for a lower premium, a large majority (85%) say they would participate in an employer’s wellness program. Fewer say they would accept a more restricted list of doctors and hospitals (49%), pay more for brand-name drugs (39%) or pay a significantly higher deductible (23%).

The survey was conducted from Sept. 25 through Oct. 9, 2018 among a probability-based sample of 1,407 adults ages 18-64 who reported having health insurance from their own or a spouse’s employer or union. Interviews were administered online and by telephone in English and Spanish using NORC’s AmeriSpeak panel. The margin of sampling error is plus or minus 3 percentage points for the full sample. Teams from the Kaiser Family Foundation and The Los Angeles Times worked together to develop the questionnaire and analyze the data. Each organization is solely responsible for its content.

Kaiser Family Foundation/LA Times Survey Of Adults With Employer-Sponsored Insurance

Authors: Liz Hamel, Cailey Muñana, and Mollyann Brodie
Published: May 2, 2019

Overview

The Survey Of Adults With Employer-Sponsored Health Insurance – the first partnership project conducted jointly by the Kaiser Family Foundation and the Los Angeles Times – explores the attitudes and experiences of adults with employer-sponsored health insurance (ESI), including views of their health plans and affordability challenges related to premiums, deductibles, and unexpected medical bills.

The survey takes a special look at those in high deductible plans (including those paired with a health savings account or HSA), those with chronic health conditions, and those with lower incomes. It also examines factors related to health plan decision-making and cost-conscious health care shopping behaviors, as well as overall views of the U.S. health care system.

Read The Los Angeles Times’ coverage:

Health insurance deductibles soar, leaving Americans with unaffordable bills

Three kids, a health plan and $15,000 in medical debt: A working family tries to make ends meet

Soaring insurance deductibles and high drug prices hit sick Americans with a ‘double whammy’

Rising health insurance deductibles fuel middle-class anger and resentment

Americans’ struggles with medical bills are a foreign concept in other countries

Trying to shop for medical care? Lots of luck with that

Not everyone has eye-popping deductibles: How one union kept medical bills in check

Executive Summary

Since the passage of the Affordable Care Act (ACA) in 2010, much attention has been paid to the parts of the U.S. health insurance landscape that were most directly impacted by the law, including the individual insurance market and expanded Medicaid programs in some states. Yet, the number of people covered by employer-sponsored health insurance in the U.S. far exceeds the number covered in the individual market or by any government program. In 2017, about 156 million people had employer-based coverage, representing almost half the total U.S. population and 60 percent of non-elderly adults.1  Surveys of employers point to the growing cost burden of health insurance for this population. Between 2008 and 2018, premiums for employer-sponsored insurance plans increased 55 percent, twice as fast as workers’ earnings (26 percent). In addition, workers are finding themselves on the hook for bigger deductibles before their insurance will kick in. Over the same time period (2008-2018), the average health insurance deductible for covered workers increased by 212 percent.2 

Against this backdrop, the Kaiser Family Foundation partnered with the Los Angeles Times to conduct a representative survey of adults with employer-sponsored health insurance.3  Some key themes from the survey are summarized here, and a full report of the findings follows.

Overall, the survey finds that most people with employer-sponsored insurance (ESI) are generally satisfied with their health plans, and large shares say they feel “grateful” and “content” about their insurance while fewer say they are “angry” or “frustrated.” However, insurance does not offer iron-clad protection against health care affordability challenges. Four in ten report that their family has had either problems paying medical bills or difficulty affording premiums or out-of-pocket medical costs, and about half say someone in their household skipped or postponed some type of medical care or prescription drugs in the past year because of the cost. Seventeen percent say they’ve had to make what they feel are difficult sacrifices in order to pay health care or insurance costs; for some, the sacrifices they report making are extreme.

The experiences and attitudes of people with employer coverage differ vastly depending on whether they are in a higher or lower deductible plan. The higher the deductible, the more likely an individual is to have negative views of their health plan, and the more likely they are to experience problems affording care or to put off care due to cost. One reason people with higher deductibles are having trouble affording care is that many of them do not have enough savings to cover the full amount of their deductible. Among those in the plans with the highest deductibles (at least $3,000 for an individual or $5,000 for a family), over half say the amount of savings they could easily access in the short term is less than the amount of their deductible.

Another group that is particularly vulnerable to health care affordability issues are those with chronic conditions. Just over half (54 percent) of those with employer-sponsored coverage say that someone covered by their plan has a chronic condition such as hypertension, asthma, a serious mental health condition, or diabetes. About half of this group reports that their family has had problems paying medical bills or difficulty affording premiums or out-of-pocket costs, compared to about three in ten of those in families without a chronic condition. The combination of a chronic condition and a high deductible leads to even higher rates of problems and worries. For example, three-quarters of those in the highest deductible plans who say someone on in their family has a chronic condition say that a family member in their household has skipped or delayed some type of medical care or prescription drugs for cost reasons in the past year.

The survey also finds that cost has taken on greater importance in health insurance decision-making over the last decade and a half. When asked to choose the most important feature in a health plan, about six in ten people with employer coverage choose cost-related factors (low premiums, deductibles, or co-pays), while about a quarter choose coverage-related factors (choice of providers or range of covered benefits). These shares are essentially the opposite of what they were in 2003, when one-third chose cost-related factors and six in ten chose range of benefits or choice of providers. Similarly, among those whose employer offered a choice of plans, the share who say they picked their plan based on the cost increased from 21 percent in 2003 to 36 percent in the current survey.

Seven in ten people with employer coverage report engaging in some type of cost-conscious health care shopping behavior in the past 12 months, the most common of which is asking for a generic instead of a brand-name drug (47 percent). Less common behaviors are those that might actually lead to lower prices on services, including shopping around at different providers to find the best price for a medical service (17 percent) and trying to negotiate with a provider for a lower price (9 percent). One selling point of high deductible health plans is that they may incentivize enrollees to engage in more cost-conscious behaviors, including price-based shopping. The survey finds mixed evidence that this is the case; while the lowest rate of reporting these behaviors occurs among those in plans with no deductible, with a few exceptions, those in high deductible plans are not significantly more likely than those in lower deductible plans to report engaging in price-based shopping. In addition, those in high deductible plans paired with a health savings account (HSA plans) are not significantly more likely than those in plans with similar deductible levels to report shopping for lower-priced health care services. Overall, those enrolled in HSA plans – who make up 18 percent of adults with employer coverage – are more likely to view them as a way to pay for current medical bills than as a way to save money for the future.

Confusion and lack of access to cost information can also be a barrier for individuals to engaging in cost-conscious health care behaviors. Two-thirds say it is difficult to find out how much medical treatments and procedures provided by different doctors and hospitals would cost them, and over four in ten say they have had difficulty understanding how much they will have to pay out of their own pocket when they use care.

Finally, while most people with employer insurance feel that the cost of health care for people like them is too high, more say the current U.S. health insurance system works well for people with employer coverage than say it works well for people on Medicare or Medicaid or those who purchase their own insurance. Asked who is to blame for high costs, majorities point the finger at pharmaceutical and insurance companies, while fewer see hospitals, doctors, or employers as deserving of blame.

Key Findings: Section 1: Profile Of Adults With Employer-sponsored Health Insurance And Overall Views Of Coverage

Sixty percent of adults ages 18-64 in the United States have health insurance coverage through an employer or union. Census data show that, compared to the general population, these adults have higher incomes and education levels and are more likely to be White or Asian and less likely to be Black or Hispanic.4 

The survey finds that most people with employer-sponsored health coverage (73 percent) say they pay at least part of their premium for their insurance, while 16 percent say their employer pays the whole thing. When asked about their annual deductible for medical care, 15 percent say they have no deductible and 44 percent report a deductible of less than $1,500 for an individual or less than $3,000 for a family (defined for the purposes of this report as “lower deductible”). Four in ten (41 percent) report having plans with higher deductible amounts, including 20 percent with deductibles between $1,500 and $2,999 for an individual or between $3,000 and $4,999 for a family (“higher deductible”) and 21 percent with deductibles of at least $3,000 for an individual or $5,000 for a family (“highest deductible”). About one in six (18 percent) report having a higher or highest deductible plan paired with a health savings account (HSA).

Figure 1: Four In Ten Adults With Employer-Sponsored Insurance Report Having High Deductible Plans

Nearly two-thirds (64 percent) of people with employer coverage say their insurance covers other family members in addition to themselves, while 36 percent report having single coverage. While nearly nine in ten (88 percent) describe their own health status as “excellent,” “very good,” or “good,” just over half (54 percent) say that they or another family member covered by their plan has a chronic condition, the most common being hypertension or high blood pressure (30 percent), a serious mental health condition (15 percent), asthma or other breathing problems (14 percent), and diabetes (11 percent).

Figure 2: Half of Those With Employer-Sponsored Insurance Say They Or A Family Member Has At Least One Chronic Condition

Overall, most people with employer coverage report being happy with their insurance. Nearly seven in ten (68 percent) give their health plan a grade of “A” or “B,” and large shares say the words “grateful” (72 percent) and “content” (69 percent) describe the way they feel about their insurance, while far fewer identify with words like “frustrated” (26 percent), “confused” (23 percent), or “angry” (14 percent). More than half (58 percent) say they think their employer is offering them the best health insurance they can afford. However, a substantial share – 42 percent – believe their employer could be providing something better.

It’s notable that these views differ greatly depending on the deductible level of an individual’s plan. For example, among those in the highest deductible plans, over half (55 percent) give their plan a grade of “C” or below, and half (51 percent) say their employer could be providing something better. While positive emotions still outweigh negative emotions for this group, the gap is much narrower, with 58 percent saying they feel “grateful,” and 50 percent “content,” while four in ten say they feel “frustrated,” 34 percent “confused,” and 23 percent “angry.”

Figure 3: Most Give Plans Passing Grades, But Less So For Those With High Deductibles
Figure 4: Most Say Employer Is Offering Best Insurance They Can, But Those With Highest Deductibles More Split
Figure 5: Positive Emotions Towards Health Plans Outweigh Negatives, But Less So For Those With High Deductibles

In addition, while most people in plans with no or lower deductibles say their health insurance has “stayed about the same” in the past 5 years, four in ten (39 percent) of those in higher deductible plans and half of those in the highest deductible plans say their insurance has “gotten worse.”

Figure 6: Those In High Deductible Plans More Likely To Say Insurance Has Gotten Worse In Past 5 Years

Key Findings: Section 2: Affordability Of Health Care And Insurance

While many employers pay for a large share of covered workers’ health insurance premiums, the survey finds that employer-sponsored health insurance does not offer iron-clad protection against health care affordability challenges. Four in ten adults with employer coverage say that in the past year they had problems paying medical bills or difficulty affording their premium, deductible, co-pays, or an unexpected medical bill for themselves or a family member. When this group is asked to say which has been the biggest problem for their family, medical bills they had to pay before meeting their deductible (31 percent) and unexpected medical bills (23 percent) top the list, while fewer say the biggest burden is their prescription drug costs (11 percent), medical visit co-pays (10 percent), or health insurance premiums (8 percent).

Figure 7: Four In Ten People With Employer Coverage Report Difficulty Affording Some Type Of Health Care Or Insurance Cost
Figure 8: Deductibles And Surprise Medical Bills Top List Of Most Difficult Affordability Problems

Among the 40 percent who report problems affording some type of health care cost in the past year, many report making various sacrifices in order to pay these costs. Two-thirds of this group (representing about a quarter of all adults with ESI) say they put off vacations or major household purchases or cut back spending on food, clothing, or basic household items. About half (one in five among the total) say they increased their credit card debt or used up all or most of their savings to pay for health care. One-third (14 percent of total) say they took on an extra job or worked more hours and a quarter (10 percent of total) reporting borrowing money from friends or family or taking money out of a long-term savings account. Smaller shares say they took out a loan, sought the aid of a charity or non-profit, changed their living situation, or used the internet to raise funds to pay for medical care.

Figure 9: Those With Employer Coverage Who Have Problems Affording Health Care Report Many Sacrifices To Pay Bills

In addition, 41 percent of those who had difficulty affording health care costs (17 percent of all adults with employer-sponsored insurance) say they feel they have had to make a difficult sacrifice in order to pay health care or insurance costs in the past 12 months. When asked to describe in their own words the most difficult sacrifice they have made, responses ranged from cancelled vacations, to skipped meals, to increased debt, to forgoing needed medical care.

Table 1: In Their Own Words: Difficult Sacrifices To Afford Health Care
Question: What is the most difficult sacrifice you’ve made in order to pay health care or health insurance costs in the past 12 months?
CategoryPercentage among those who made a difficult sacrificePercentage among all adults with ESIOpen-ended responses
Cut back on extras (vacation, eating out, entertainment)17%3%“Not being able to have extra money to do leisure/recreational things I would like. Have to focus money on ‘needs’ not ‘wants.’”

“Cancelled 25th wedding anniversary plans/vacation”

Cut back on food/eat less122“Having trouble affording food for my kid and myself”

“Me not eating so my kids can”

“Ate like a bird sometimes”

Skipping/being late on other bills102“I missed several car payments”

“Picking which bill to pay and not to pay”

Taking money out of savings/not able to save102“Take money out of my 401k and personal savings account”

“Not being able to save/put away money”

Cut back in general71“Cutting our budget everywhere”

“Cut back on everything”

Increasing credit card/other debt71“Raising my credit card debt so much. Now with interest I only have to pay more.”

“Taking out more debt to pay down a medical bill”

Increasing work hours/going back to work71“I had to work 3 jobs at once. 1 full time and 2 part time jobs. Working from 4:30AM until 11pm”
Skipping care/medication71“Allowing my health to deteriorate because it’s too expensive to keep up with the cost of care”

“Not getting the medical treatment I need. I need two surgeries and cannot afford them at this time.”

Cut back on clothing, children’s items61“Not getting gifts for my grandchildren, birthdays and holidays”

“Cut back on purchases for our children, such as clothes”

Unpaid medical bills can also lead to longer-term financial effects for some people. About one in five (19 percent) say that someone in their household has been contacted by a collection agency in the past 12 months because of medical bills, and 9 percent say they have at some point declared personal bankruptcy because of medical bills (including 2 percent who say they did so in the past 12 months).

In addition to making sacrifices to afford care, about half (51 percent) of adults with employer health coverage report that they or someone in their household has skipped or delayed some type of medical care or prescription drugs in the past 12 months because of the cost. This includes about a third each who report relying on home remedies or over-the-counter drugs instead of going to see a doctor (35 percent) or putting off or postponing needed care (33 percent), about a quarter (24 percent) who report not getting a recommended medical test or treatment, and about one in five (18 percent) who report not filling a prescription, cutting pills in half, or skipping doses of medicine because of the cost.

Figure 10: Half Of Those With ESI Say Someone In Family Skipped Or Postponed Needed Care Or Rx Because Of The Cost

Both difficulty affording health care expenses and forgoing or delaying care due to cost are more commonly reported among certain groups, including those with lower incomes, those in higher deductible plans, and those who say someone covered by their plan has a chronic health condition. For example, while 40 percent of all adults with employer coverage say they’ve had problems paying medical bills or difficulty affording health care or insurance costs for themselves or their family in the past year, the shares are higher among those with annual household incomes below $40,000 (65 percent), those who say someone covered by their plan has a chronic condition (49 percent), and those in the highest deductible plans (49 percent). Similarly, while about half overall report that someone in their household skipped or postponed some type of health care in the past year because of the cost, the share rises to around six in ten among those with the lowest incomes, the highest deductibles, or a chronic condition.

Figure 11: Lower Incomes, Higher Deductibles, And Chronic Conditions Associated With Health Care Affordability Challenges
Figure 12: Lower Incomes, High Deductibles, And Chronic Conditions Associated With Skipping Or Postponing Care Due To Cost

Key Findings: Section 3: The Experiences Of Those With High Deductibles And Those With Chronic Conditions

As noted above, people with employer sponsored health plans that have high deductibles are more likely to report problems affording health care, and more likely to postpone or forgo health care services for cost reasons. One contributing factor may be the fact that many people in higher deductible plans do not have enough savings to cover the full amount of their deductible. When asked how much they have in savings that could easily be accessed in the short term, three in ten (31 percent) of those in higher deductible plans and more than half (56 percent) of those in the highest deductible plans name an amount that is less than the amount of their deductible.

Figure 13: Over Half Of Those In Highest Deductible Plans Report Personal Savings Less Than Amount Of Their Deductible

In addition, most people enrolled in plans with high deductibles say they would not be able to pay a bill equal to the full amount of their deductible without going into debt. When asked how they would pay an unexpected medical bill equal to the amount of their deductible, one-third of those in plans with high deductibles say they would either pay the bill at the time of service or put it on a credit card and pay it off at their next statement. About half say they would go into some type of debt to pay the bill, either by putting it on a credit card and paying it off over time (27 percent), setting up a payment plan with the provider (17 percent), or borrowing money from a bank, payday lender, or friends and family (5 percent). One in six (16 percent) say they would not be able to pay such a bill at all.

Those in high deductible plans who have lower incomes are even less likely to say they could afford such a bill. Among those in high deductible plans who have annual household incomes of $40,000 or less, one-third (32 percent) say they would not be able to pay a bill in the full amount of their deductible at all, while just 14 percent say they would pay it off right away or at the next credit card statement.

Figure 14: Two-Thirds In Higher Or Highest Deductible Plans Could Not Pay A Bill Equal To Deductible Without Going Into Debt
Figure 15: One-Third Of Those With Low Incomes And High Deductibles Would Not Be Able To Pay Bill Equal To Deductible

Another group that is particularly vulnerable to health care affordability issues are people with chronic conditions. Those who say someone covered by their plan has a chronic health condition (a group that makes up 54 percent of people with employer plans) are about twice as likely as others to report problems paying medical bills (36 percent versus 16 percent). They are also much more likely to say they’ve had difficulty affording medical bills before meeting their deductible, unexpected medical bills, co-pays, and monthly health insurance premiums.

Figure 16: Those In Families With A Chronic Health Condition More Likely To Experience Problems Affording Health Care

Drilling down into the consequences of these affordability problems reveals more about the financial burden of health care on families with chronic conditions. Overall, more than one-third of those with a chronic condition in the family say they put off vacations or major household purchases (36 percent) or cut back spending on food, clothing, or basic household items (35 percent) in order to pay for health care and insurance costs. Nearly three in ten (28 percent) say they increased their credit card debt, about a quarter (26 percent) say they used up all or most of their savings, and one in five (19 percent) say they took on an extra job or worked more hours in order to pay for health care. Other consequences, such as borrowing money, seeking charity aid, or changing living situation were less common, but still occurred at about twice the rate among people in families with a chronic condition compared to those without such a condition.

Figure 17: Those In Families With Chronic Health Conditions More Likely To Report Financial Impacts Of Health Care Affordability Problems

Those with chronic conditions are also more likely to report forgoing or delaying health care because of the cost, and this is particularly true for those in plans with high deductibles. For example, 42 percent of those who say someone covered by their plan has a chronic condition say there was a time in the past year when they or another family member put off or postponed getting health care they needed, compared with 23 percent of those without a chronic condition. Among those with chronic conditions who are in the highest deductible plans, the share rises to 60 percent. Similarly, three in ten (31 percent) of those in families with a chronic condition say they skipped a doctor-recommended test or medical treatment in the past year for cost reasons, twice the share as among those with no chronic condition, and rising to 44 percent among those with chronic conditions in the highest deductible plans. Overall, 60 percent of all those with a family chronic condition say someone in their household skipped or postponed some type of care or medicine for cost reasons, rising to 75 percent among those in the highest deductible plans.

Table 2: Skipping And Postponing Needed Care Because Of Cost, By Family Chronic Condition And Health Plan Deductible Level
Percent who say they or a family member did the following in the past 12 months…No chronic condition in familyAny family member covered by plan has chronic condition
TotalNo/Lower DeductibleHigher DeductibleHighest Deductible
Put off or postponed getting health care they needed23%42%34%49%60%
Relied on home remedies or OTC drugs instead of going to see a doctor2841334658
Have not gotten a medical test or treatment recommended by a doctor1531243544
Not filled a prescription, cut pills in half, or skipped doses of a medicine1223192335
Yes to any4060526975

The combination of a chronic condition and a high deductible can also lead families to worry about affording health care in the future. For example, among those with a chronic condition in the family, about half of those in the highest deductible plans say they are not confident in their ability to pay for the usual medical costs they and their family require, and almost two-thirds are not confident they could pay for a major illness.

Figure 18: Among Those With High Deductibles And Chronic Conditions, Large Shares Are Not Confident About Affording Major Illness

Key Findings: Section 4: Health Insurance Decision-making And Trade-offs

The survey finds that at the same time premiums and deductibles have been rising for people with employer-sponsored coverage, cost has taken on greater importance in health insurance decision-making compared to previous years. For example, when asked to choose the most important feature in a health plan, one quarter cite a low monthly premium, 18 percent choose a low deductible, and 16 percent cite low co-pays, amounting to six in ten (59 percent) choosing a cost-related factor. About a quarter (26 percent) choose coverage-related factors including having a wide range of benefits (17 percent) or a wide choice of doctors and hospitals (10 percent). These shares are essentially reversed from a KFF survey conducted in 2003, when one-third of people with employer coverage chose cost-related factors as the most important feature in a health plan and six in ten chose a wide range of benefits or choice of providers.

Figure 19: Cost Factors Rated More Important Now Than In 2003, Benefits And Provider Choice Less Important

Another trend point shows a similar pattern. Among those whose employer offered a choice of plans, the share who say they picked their plan based on the cost increased 15 percentage points, from 21 percent in 2003 to 36 percent in the current survey.

Figure 20: Compared To 2003, Cost Now Rated More Important, Choice Of Providers Less Important In Plan Choice

When asked about trade-offs between premiums and out-of-pocket costs, people with ESI are pretty evenly divided between saying they would prefer a plan with a relatively low monthly premium and higher out-of-pocket costs (52 percent) or one with a relatively high monthly premium and lower out-of-pocket costs (47 percent). However, those with higher household incomes lean towards lower premiums and higher out-of-pocket costs, while those with lower incomes lean in the opposite direction.

Figure 21: Preference Split Between Plans With Higher Or Lower Premium, Out-Of-Pocket Costs

Despite this increased emphasis on cost, there is no great enthusiasm among people with employer plans for several trade-offs that might lower insurance premiums. About three-quarters say they would not be willing to pay a significantly higher deductible in exchange for a lower premium (perhaps because deductibles have risen so much already), and six in ten say they would not be willing to pay more for brand name prescription drugs. However, about half say they would be willing to accept a more restricted list of providers in exchange for lower premiums, and a large majority (85 percent) say they’d be willing to participate in a wellness program.

Figure 22: Most Willing To Participate In Wellness Program To Lower Premium, One In Four Willing To Pay Higher Deductible

Key Findings: Section 5: Views And Experiences Related To Health Savings Accounts

Just under one in five (18 percent) of all adults with employer coverage report being in a high deductible health plan paired with a Health Savings Account (HSA). Most of these people report making relatively modest contributions and having relatively modest savings in their HSA, particularly if they have lower incomes. For example, about half (47 percent) of people with an HSA plan say they have contributed less than $1,000 to their account in the past 12 months, and just 11 percent say they’ve contributed $5,000 or more. Among those with household incomes under $75,000 a year, 72 percent say they contributed less than $1,000 and just 3 percent put in at least $5,000.

Figure 23: Those With Higher Incomes And Highest Deductibles Report Greater HSA Contributions

Few seem to be able to save much money in these accounts over time. Overall, about three in ten (31 percent) say they have at least $2,000 saved in their HSA account, including 17 percent who have at least $5,000. Among those with incomes under $75,000, fewer – 22 percent – report having at least $2,000 saved, including one in ten (11 percent) who have at least $5,000.

Figure 24: Few Of Those With HSA Plans Report Having At Least $5,000 Saved In HSA Account

The survey finds that individuals with HSA plans are more likely to view them as a way to pay for current medical bills (68 percent) than as a way to save money for the future (32 percent). This also bears out in their self-reported behaviors: while seven in ten (72 percent) say they have used their HSA to pay medical bills in the past 12 months, far fewer – 21 percent – say they use their HSA to invest in stocks, bonds, or mutual funds.

Figure 25: HSAs Viewed More As A Way To Pay Medical Bills Rather Than Save For The Future

Key Findings: Section 6: Cost-conscious Health Care Shopping Behaviors

The survey asked about a list of seven different cost-conscious health care shopping behaviors, and finds that seven in ten people with ESI report engaging in at least one of these behaviors in the past 12 months. The most common of these are asking for a generic instead of a name brand drug (47 percent) and checking with a provider or health plan beforehand to find out the cost of a procedure (37 percent) or office visit (36 percent). Less commonly-reported behaviors are those that might actually lead to lower prices on health care services, including using an online tool to research the cost of different providers (23 percent), shopping around at different providers to find the best price for a medical service (17 percent), and trying to negotiate with a provider for a lower price (9 percent).

When consumers do try to negotiate prices, they report being successful less than half of the time; of the 9 percent who say they tried to negotiate with a provider, 43 percent say they were able to get a lower price while 57 percent say they were not.

Figure 26: Seven In Ten Report Engaging In At Least One Health Care Shopping Or Cost-Saving Behavior

One selling point of high deductible health plans is that they may incentivize enrollees to engage in more cost-conscious behaviors, including price-based shopping. The survey finds mixed evidence about whether this is occurring among people with employer-based coverage. While the lowest rates of reporting cost-conscious behaviors occur among those in plans with no deductible, those in high deductible plans are not significantly more likely than those in lower deductible plans to report engaging in most of the behaviors asked about in the survey. There are two exceptions: those in plans with high deductibles are more likely than those with lower deductibles to say they’ve asked for a generic rather than a name brand drug (55 percent versus 43 percent) and that they’ve used an online tool to compare the cost of different providers (30 percent versus 22 percent).

Similarly, HSA plans are viewed as a way to give consumers more control over their medical care and to encourage cost-conscious behaviors. To the extent that the survey finds people in HSA plans are engaging in more cost-conscious behaviors, it seems to be due to the deductibles associated with these plans rather than the savings account element, since those in high deductible plans without an HSA are not significantly more likely than those in HSA plans to report these behaviors.

Table 3: Reports Of Cost-Conscious Health Care Shopping Behaviors, By Health Plan Deductible Level And Health Savings Account Participation
Percent who say they did each of the following in the past 12 months…No deductibleLower deductibleHigher/Highest deductible
TotalNo HSAWith HSA
Asked a doctor or pharmacist for a generic drug to save money33%43%55%58%53%
Checked with a provider or health plan before a procedure or hospital stay to find out how much they have to pay2938393644
Checked with their provider or health plan before an office visit to find out how much they have to pay2936403843
Talked to a provider or health plan about the cost of a prescription drug1830333235
Used an online tool to research the cost of different health care providers922302931
Attempted to shop around at different providers to find the best price417211925
Tried to negotiate with a doctor, hospital, or other provider to get a lower price5911815
Yes to any5268797782

Confusion and lack of access to cost information can also be a barrier for individuals to engaging in cost-conscious health care behaviors. Two-thirds of people with employer coverage say it is difficult to find out how much medical treatments and procedures provided by different doctors and hospitals would cost them. In addition, four in ten say they have had difficulty understanding what their health plan will cover (40 percent) and a similar share report difficulty understanding how much they will have to pay out of their own pocket when they use care (44 percent). 

Figure 27: Most Say Cost Information Is Hard To Find, Four In Ten Report Difficulty Understanding Cover Or What They’ll Pay

Key Findings: Section 7: Perceptions Of Health System Winners, Losers, And Who’s To Blame

When asked how well the current health insurance system in the United States works for various groups, fewer than a quarter of people with employer coverage say it works “very well” for any group, with the exception of wealthy people (70 percent). Still, a large majority believes the system works at least “somewhat well” for people with employer health coverage (79 percent), somewhat higher than the share who say the same about people covered by Medicare (65 percent) or Medicaid (63 percent), and substantially higher than the share saying the system works well for those who buy their own insurance (45 percent).

Figure 28: More Say Health Insurance System Works Well For Those With Employer Coverage Than Other Coverage Types

While almost two-thirds (65 percent) of people with employer coverage feel the current health insurance system in the U.S. works at least “somewhat well” for people like them, the percentage varies by income and deductible level. For example, 80 percent of those in a plan without a deductible say the system works well for people like them, compared to about half (48 percent) of those in the plans with the highest deductibles. Similarly, about three-quarters of those with annual household incomes of at least $100,000 feel the system works well for them, compared with half (49 percent) of those with incomes under $40,000.

Figure 29: Those With Higher Deductibles, Lower Incomes Less Likely To Feel U.S. System Works Well For People Like Them

While most feel the system is working well for them, about eight in ten (78 percent) people with employer coverage say the cost of health care for people like them is too high, with near-universal agreement across demographic groups. Asked who they blame for the high cost of health care, people mainly point to two groups that have long been named by the public as culprits of high costs: pharmaceutical and insurance companies, with about six in ten saying each deserves “a lot of blame.” About three in ten also place a lot of blame on hospitals (32 percent), the Affordable Care Act (29 percent) and the Trump Administration’s recent actions on health care (28 percent), while fewer place a lot of blame on doctors (15 percent). Echoing the finding that a large majority says they feel “grateful” for their employer-provided health insurance, just 7 percent say employers deserve a lot of blame for the high cost of health care, while two-thirds say employers deserve “just a little” or “no blame at all.”

Figure 30: Pharma And Health Insurance Companies Receive Most Blame For High Costs, Employers Less So

Not surprisingly, there are partisan differences in the share who blame the Affordable Care Act (ACA) and the Trump Administration for the high cost of health care. Among those who feel costs for people like them are too high, about half (49 percent) of Democrats and just 4 percent of Republicans say the Trump Administration’s actions on health care deserve a lot of blame, while six in ten Republicans (59 percent) and just 10 percent of Democrats place a lot of blame on the ACA. Among independents, 27 percent say the ACA deserves a lot of blame and 21 percent say the same about the Trump Administration’s recent actions.

Figure 31: Across Partisans, Large Shares Blame Pharmaceutical And Health Insurance Companies For High Health Care Costs

Methods

The Kaiser Family Foundation/Los Angeles Times Survey of Adults with Employer-Sponsored Health Insurance is based on interviews with a probability-based sample of 1,407 respondents between the ages of 18 and 64 who reported having health insurance from an employer or union (excluding those covered by a parent’s employer). Interviews were administered online and by telephone from September 25 through October 9, 2018 in English and Spanish.

Teams from the Kaiser Family Foundation and The Los Angeles Times worked together to develop the questionnaire and analyze the data, and both organizations contributed financing for the survey. Each organization is solely responsible for its content.

NORC at the University of Chicago conducted sampling, interviewing, and tabulation for the survey using the AmeriSpeak Panel, a representative panel of adults age 18 and over living in the United States. AmeriSpeak Panel members are recruited through probability sampling methods using the NORC National Sample Frame, an address-based sampling frame. Panel members who do not have internet access complete surveys via telephone, and internet users complete surveys via the web (for this survey, 60 respondents completed via phone and 1,347 via web).5  For this study, panelists with lower incomes were selected at disproportionately higher rates than those with higher incomes in order to allow for separate analysis of low-income people with employer-sponsored insurance.

The combined results have been weighted to adjust for the fact that not all survey respondents were selected with the same probability, to address the implications of sample design, and to account for systematic nonresponse along known population parameters. The first weighting stage addressed differences in probability of selection for the AmeriSpeak Panel and accounted for differential nonresponse to the AmeriSpeak screening interview. At this stage, an adjustment was also made to account for the oversampling of lower-income panelists and to account for differential nonresponse to the survey screening interview.

In the second weighting stage, the sample was adjusted to match known demographic distributions of the U.S. population ages 18-64 with employer-sponsored health insurance using the following parameters: age, age by sex, age by education, gender by education, education within non-Hispanic whites, race/ethnicity, Census Division, and household income. Demographic weighting parameters were based on the U.S. Census Bureau’s March 2018 Annual Social and Economic Supplement of the Current Population Survey.

The margin of sampling error including the design effect for the full sample is plus or minus 3 percentage points. All statistical tests of significance account for the effect of weighting. Numbers of respondents and margins of sampling error for key subgroups are shown in the table below. For results based on other subgroups, the margin of sampling error may be higher. Sample sizes and margins of sampling error for other subgroups are available by request. Note that sampling error is only one of many potential sources of error in this or any other public opinion poll.

GroupN (unweighted)M.O.S.E.
Total adults ages 18-64 with employer-sponsored insurance1,407±3 percentage points
Deductible level
Zero Deductible189±9 percentage points
Lower deductible647±5 percentage points
Higher deductible280±7 percentage points
Highest deductible284±7 percentage points

Kaiser Family Foundation public opinion and survey research and NORC at the University of Chicago are both charter members of the Transparency Initiative of the American Association for Public Opinion Research.

Endnotes

  1. State Health Facts. (n.d.). Retrieved April 2019, from https://modern.kff.org/state-category/health-coverage-uninsured/ ↩︎
  2. Claxton, G., Rae, M., Long, M., Damico, A., Whitmore, H. (2018, October 3). Kaiser Family Foundation 2018 Employer Health Benefits Survey. Retrieved from https://modern.kff.org/health-costs/report/2018-employer-health-benefits-survey/ ↩︎
  3. The survey includes adults ages 18-64 who say they get their health insurance from their own or a spouse’s employer or union. Those ages 65 and older are excluded since they are generally eligible for coverage through Medicare. ↩︎
  4. State Health Facts. (n.d.). Retrieved April 2019, from https://modern.kff.org/state-category/health-coverage-uninsured/nonelderly-with-employer-coverage/ ↩︎
  5. More details on NORC’s AmeriSpeak panel, including sample frame and recruitment methods, can be found at http://www.norc.org/Research/Capabilities/Pages/amerispeak.aspx.   ↩︎

Medicaid’s Prescription Drug Benefit: Key Facts

Published: May 1, 2019

Medicaid provides health coverage for millions of Americans, including many with substantial health needs. Prescription drug coverage is a key component of Medicaid for many beneficiaries, such as children, non-elderly adults, and people with disabilities, who rely on Medicaid drug coverage for both acute problems and for managing ongoing chronic or disabling conditions. (Medicaid beneficiaries who also have Medicare receive drug coverage through Medicare.). Though the pharmacy benefit is a state option, all states cover it, and, within federal guidelines about pricing and rebates, administer pharmacy benefits in different ways. After a sharp spike in 2014 due to specialty drugs and expansion under the Affordable Care Act (ACA), Medicaid drug spending growth has slowed, similar to the overall US pattern; however, state policymakers remain concerned about Medicaid prescription drug spending as spending is expected to grow in future years. Due to Medicaid’s role in financing coverage for high-need populations, it pays for a disproportionate share of some high cost specialty drugs, and due to the structure of pharmacy benefit, Medicaid must cover upcoming “blockbuster” drugs. Policymakers’ actions to control drug spending have implications for beneficiaries’ access to needed prescription drugs. This fact sheet provides an overview of Medicaid’s prescription drug benefit and recent trends in spending and utilization.

Though generic drugs account for the large majority of drug utilization in Medicaid – 86% of prescriptions in 2017 — brand name drugs accounted for 79% of drug spending.

How does Pricing and Payment for Prescribed Drugs Work in Medicaid?

The total amount paid by Medicaid for a given drug is a factor of several inputs: 1) the dispensing fee paid to the pharmacist; 2) the amount paid to the pharmacy for the ingredients of a drug; and 3) the rebate received from the manufacturer. States have flexibility to set professional dispensing fees, but there are federal requirements for the other inputs.

Ingredient Costs and Payment

Medicaid reimburses pharmacies for the cost of drugs dispensed to beneficiaries based on the actual acquisition cost (AAC) for a drug. In general, Medicaid does not purchase drugs directly from manufacturers or wholesalers; rather, Medicaid pays for the cost of drugs dispensed to Medicaid beneficiaries through pharmacies. The federal government requires states to use AAC to set payment to pharmacies and encourages states to use the National Average Drug Acquisition Cost (NADAC) data as the measure of AAC.1 ,2  The NADAC is intended to be a national average of the prices at which pharmacies purchase a prescription drug from manufacturers or wholesalers, including some rebates.

Pharmacies that dispense drugs to Medicaid beneficiaries purchase drugs from manufacturers or wholesalers, negotiating prices for drugs. Payment between the pharmacy and the manufacturer or wholesaler (to acquire and stock the drug) is a proprietary process, negotiated based off the manufacturer-set list prices for a drug. Manufacturers do not provide public information on how they set this list price and historically have not been required to explain changes in a product’s list price. While the list prices most directly affect the wholesaler and pharmacy, they also affect Medicaid reimbursement schedules, as they are an input into the AAC.

The Medicaid Drug Rebate Program

Federal law requires manufacturers who want their drugs covered under Medicaid to rebate a portion of drug payments to the government,3  and in return, Medicaid must cover almost all FDA-approved drugs produced by those manufacturers.4 ,5  The formula for the amount of the rebate is set in statute6  and varies by type of drug (brand or generic).7  The structure of the federal Medicaid rebate factors in the “best price” charged to any other buyers and ensures that Medicaid will always receive a higher rebate than other payers, with some exceptions.8  It also includes an inflationary component that requires additional rebates when average manufacturer prices for a drug increase faster than inflation.9  Rebates apply regardless of whether a state pays for prescription drugs on a fee-for-service basis or includes them in capitation payments to managed care plans.

In addition to federal statutory rebates, most states negotiate with manufacturers for supplemental rebates. Some states have formed multi-state purchasing pools when negotiating supplemental Medicaid rebates to increase their negotiating power. In addition, Medicaid managed care plans may negotiate their own rebate agreements with manufacturers.

Statutory and supplemental rebates account for a sizeable share of gross prescription drug spending, accounting for 55% of aggregate drug spending in 2017 (Figure 1).10  In recent years, rebates as a share of gross Medicaid drug spending have increased (Figure 1), leading to flat or declining net Medicaid spending for prescription drugs. The specific rebate on a given drug is proprietary for both statutory and supplemental rebates.

Figure 1: Medicaid Drug Spending and Rebates, FY2014-17

How do states administer the Medicaid pharmacy benefit?

States are not required to cover prescription drugs under Medicaid, but all states opt to include this service in Medicaid. Within federal rules regarding the federal rebate agreement and medical necessity requirements, states have flexibility to administer and manage the pharmacy benefit within their Medicaid programs. States generally rely on two, intersecting levers to do so: 1) use of managed care and/or pharmacy benefit managers (PBMS) and 2) utilization controls.

Managed Care and Pharmacy Benefit Managers

As more states have enrolled additional Medicaid populations into managed care arrangements over time and states have included pharmacy benefits in managed care contracts, managed care organizations (MCOs) have played an increasingly significant role in administering the Medicaid pharmacy benefit. Most states contract with MCOs to provide services to Medicaid beneficiaries. Under some of these arrangements, states pay MCOs a monthly fee (capitation rate) to cover the cost of services provided to enrollees and any administrative expenses. States may include all Medicaid services in these contracts or they may “carve-out” certain services from capitation rates. Under the ACA, states are able to collect rebates on prescriptions purchased by MCOs and as a result, many states have chosen to “carve-in” the pharmacy benefit to their managed care benefits. Of the 39 states contracting with comprehensive risk-based MCOs in 2018, 35 states reported that the pharmacy benefit was carved in, with some states reporting exceptions such as high-cost or specialty drugs.11 

Many states also use pharmacy benefit managers (PBMs) in their Medicaid prescription drug programs. PBMs perform financial and clinical services for the program, administering rebates, monitoring utilization, and overseeing preferred drug lists.12  PBMs may be used regardless of whether the state administers the benefit through managed care or on a fee-for-service basis.

Utilization Management

Most states use an array of measures to control utilization of prescription drugs in Medicaid. Because most manufacturers participate in the Medicaid Drug Rebate Program,13  Medicaid essentially maintains an open formulary in which, states are required to provide nearly all prescribed drugs made by manufacturers.14 ,15  However, state Medicaid programs have used drug utilization management techniques to contain pharmacy costs for many years. Most commonly, state Medicaid programs maintain a preferred drug list (PDL) of outpatient prescription drugs,16  which is a list of drugs states encourage providers to prescribe over other drugs. A state may require a prior authorization for a drug not on a preferred drug list. Often, drugs on PDLs are cheaper or include drugs for which a manufacturer has provided supplemental rebates. Other strategies include implementing prescription limits or using state Maximum Allowable Cost (MAC)17  programs.

Following an uptick in 2014 and 2015 that reflected both the introduction of high-cost specialty drugs and increased utilization due to the ACA expansion, Medicaid prescription drug utilization and spending growth slowed in 2016 and 2017. From 2014 to 2017, Medicaid prescription drug utilization and spending largely tracked each other in the aggregate: Medicaid outpatient drug utilization increased from 621.7 million prescriptions in 2014 to 752.9 million in 2017 while spending before rebates also increased from $45.9 billion to $63.6 billion over the same period. Growth in both utilization and spending was higher from 2014-2015 than from 2015-2017. However, these aggregate amounts belie underlying changes in utilization patterns and spending for Medicaid prescription drugs. Most notably, recent years have seen changes in the mix of generic versus brand drugs and the rise of specialty drugs and biologics.

Though generic drugs account for the large majority of drug utilization in Medicaid, brand name drugs account for most drug spending. Because generic drugs are lower cost but still therapeutically equivalent to brand name drugs, most state Medicaid programs require generic substitution unless the prescriber specifies that the brand is medically necessary.18 ,19  Generic drugs accounted for the vast majority of prescription drug volume in Medicaid from 2014 through 2017. In addition, the average annual increase in number generic prescription drugs covered through Medicaid outpaced brand name drugs, leading to a small increase in their share of total prescription volume (from 84% to 86%) (Figure 2). However, generic drugs accounted for a relatively small share of Medicaid spending on drugs before rebates from 2014 through 2017, and this share declined slightly over time (from 25% to 21%) (Figure 2). This growth in brand spending reflects national trends caused by the launch of expensive new drugs during the period and price increases for some brand name drugs, such as insulin, for which there are no generic versions.20 

Figure 2: Number and Spending for Medicaid Outpatient Prescriptions, by Brand/Generic Status, 2014-2017

While generics are less expensive than brand name drugs, the cost of generics has also been rising in recent years.21  These price increases reflect a combination of factors including decreasing competition within the generic market and drop in the number of generic manufacturers, as well as delays in FDA generic approvals, supply or manufacturing challenges for come drugs, among others.22  Despite the inflationary component in the rebate calculation, the complex, interrelated nature of pricing and reimbursement means that cost increases are not necessarily limited for generic drugs in Medicaid. Additionally, some believe that even limiting Medicaid spending for generics to inflation is problematic, as the expectation is that the price of generic drugs will decline over time due to competition.

In recent years, much attention in Medicaid pharmacy issues has been focused on high-cost blockbuster or “specialty” drugs, which are generally drugs that are expensive and/or require special administration. The most notable example of this attention is direct acting antivirals (DAAs), such as Sovaldi and Harvoni, used to treat hepatitis C (HCV). These drugs were a major advance in the treatment of HCV but carried a list price (initially $84,000 for a course of treatment with Sovaldi) that posed a challenge to state Medicaid program financing, even with the required rebate. Because a disproportionate number of people with HCV are enrolled in public programs, Medicaid financed a large share of DAA treatment.23  Increased competition within the class has led to some decline in list prices,24  but DAAs remain expensive, and antivirals account for a substantial share of Medicaid drug spending.25  Some states, such as Louisiana and Washington, are pursuing new approaches to further manage DAA costs while extending or maintaining access for people with HCV (see Box 1).

A related area of focus in recent years is biologics, which are products, such as drugs or vaccines, derived from living organisms with chemical structures more complicated than traditional small molecule drugs. While biologics cannot, by nature, have a technical generic equivalent, there are “biosimilars,” or products deemed “highly similar” or “interchangeable” with a referenced biologic.26  Biologics tend to be priced expensively and face less competition from biosimilars than small molecule brand drugs face from generics. Additionally, although biosimilar competition does lower the price of biologics, it does so to a lesser degree compared with the effect of generic entry on small-molecule drug market.27  As a result, Medicaid spending on biologics (14% of prescription drug spending) is outsized compared to the number of prescriptions that Medicaid fills (less than 1 percent of total Medicaid prescriptions).28 

What are recent policy initiatives in Medicaid pharmacy benefits?

Both state and federal policymakers are undertaking efforts to control prescription drug costs. Much state activity in Medicaid pharmacy benefits is focused on the goal of obtaining greater supplemental rebates from manufacturers. Some states are focusing their efforts on high-cost drugs. State are also pursuing broader drug cost initiatives that have implications for Medicaid. At the federal level, the Trump Administration has proposed or undertaken a number of actions targeted at prescription drug costs, many of which have implications for Medicaid.29  Congress is considering a host of legislative proposals related to prescription drugs, such as action to make technical changes to Medicaid rebate rules. (See examples in Box 1).

As policymakers move ahead with efforts to address Medicaid prescription drug spending, understanding the basic structure of the pharmacy benefit and recent trends can help illuminate potential direct and indirect effects, including those on access to care.

Box 1: Examples of State and Federal Actions onMedicaid Prescription Drug Costs

State EffortsNegotiate greater supplemental rebates from manufacturers:

  • New York uses a spending growth cap, under which the state targets drugs with high or quickly-growing costs for additional supplemental rebates or strict utilization review.
  • Other states, including California, are looking into leveraging purchasing power across state programs to obtain greater rebates.

Streamline the supply chain:

  • Ohio and Kentucky have undertaken efforts to streamline the supply chain by eliminating or renegotiating contracts with PBMs.

Focus on high-cost drugs:

  • Louisiana is pursuing a subscription payment model (often called the “Netflix” model) for HCV drugs30 , where the state pays a fixed cost to a manufacturer in exchange for an unlimited number of prescriptions for DAAs for individuals in Medicaid or state prisons.31 
  • Massachusetts32  and Oklahoma,33  are using or proposing value-based contracts for specific drugs, in which payment and rebates are based on a drug’s effectiveness or patient outcomes.

Broader state initiatives:

  • Some states have targeted the rising cost of generics including proposed laws to prevent price gouging and lawsuits to recoup damages from alleged collusion in price increases.
  • Policies to make pricing information more broadly available34  often apply beyond Medicaid but could provide information to help policymakers identify Medicaid pharmacy spending.

Federal Efforts

Trump Administration actions/proposals:35 

  • The FDA has taken steps and announced plans to increase competition among generics36  and biosimilars.37 ,38 
  • The Administration has called for a new Medicaid demonstration authority limited to five states that would allow state Medicaid agencies to create their own Medicaid formularies.
  • Proposed changes to safe harbor rules to encourage point-of-sale rebates for Medicare beneficiaries would also affect Medicaid pharmacy prices.

Congressional/legislative proposals:

  • Technical changes would make it harder for manufacturers to lower their rebate obligations.39 
  • Other policy proposals include elimination of the drug rebate cap, which would increase the rebates due to the inflationary component, and creation of a grace period following introduction of new drugs during which states are not required to cover that drug.
  • Proposals focused on drug spending in Medicare, including proposals to develop alternative payment structures, such as value-based payments would affect Medicaid’s best price requirement.40 

 

  1. Covered Outpatient Drugs Final Rule, Federal Register, Vol. 81, No. 20, February 1, 2016, https://www.gpo.gov/fdsys/pkg/FR-2016-02-01/pdf/2016-01274.pdf. ↩︎
  2. See “Retail Price Survey,” CMS, accessed February 15, 2018, https://www.medicaid.gov/medicaid/prescription-drugs/retail-price-survey/index.html. ↩︎
  3. Participating manufacturers pay rebates directly to states, and states retain a share of the rebate in proportion to their share of the cost of the drug (based on the federal matching rate). The federal share of the rebate is obtained through a reduction in state claims on federally-matched quarterly Medicaid expenditures. ↩︎
  4. 42 USC § 1396r-8(a)(1). ↩︎
  5. There are some exceptions to this rule. For example, states can opt to exclude certain classes of drugs (e.g., cosmetic or hair growth drugs, fertility drugs, smoking cessation or weight loss drugs). States can also require generic substitution ↩︎
  6. 42 U.S.C. 1396r-8 (c) ↩︎
  7. For brand name drugs, the rebate formula is 1) the greater of either i) 23.1% * (Average Manufacturer Price, AMP) or ii) AMP-Best Price, plus 2) the inflationary component, with the exception of certain clotting factors and drugs approved exclusively for pediatric indications. For generic drugs, the rebate formula is 13%*AMP, plus the inflationary component. ↩︎
  8. Medicaid statute defines Best Price as “the lowest price available from the manufacturer during the rebate period to any wholesaler, retailer, provider, health maintenance organization, nonprofit entity, or government entity within the United States.” There are many important exclusions, including the Department of Veterans Affairs, the 340B program, the Department of Defense, the Public Health Service, the Indian Health Service. The Best Price includes rebates in general, but not Medicaid supplemental rebates or rebates provided through the Medicaid Drug Rebate Program. 42 U.S.C. 1396r-8 (c)(1)(C). ↩︎
  9. 42 U.S.C. 1396r-8 (c). See also “Medicaid Payment for Outpatient Prescription Drugs,” (Washington D.C., MACPAC, March 2017), https://www.macpac.gov/wp-content/uploads/2015/09/Medicaid-Payment-for-Outpatient-Prescription-Drugs.pdf. ↩︎
  10. MACStats: Medicaid and CHIP Data Book, MACPAC, December 2018, “Exhibit 28: Medicaid Gross Spending and Rebates for Drug by Delivery System, FY 2017 (millions)”, https://www.macpac.gov/wp-content/uploads/2018/12/December-2018-MACStats-Data-Book.pdf. ↩︎
  11. Kaiser Family Foundation and Health Management Associates, Sates Focus on Quality and Outcomes Amid Waiver Changes: Results from a 50-State Medicaid Budget Survey for State Fiscal Years 2018 and 2019, https://modern.kff.org/medicaid/report/states-focus-on-quality-and-outcomes-amid-waiver-changes-results-from-a-50-state-medicaid-budget-survey-for-state-fiscal-years-2018-and-2019/ ↩︎
  12. States that use PBMs in administering the prescription drug benefit in a fee-for-service setting pay the PBM administrative fees for these services. See Medicaid Pharmacy Trend Report, Second Edition, (Magellan Rx Management, 2017), https://www1.magellanrx.com/media/671872/2017-mrx-medicaid-pharmacy-trend-report.pdf. ↩︎
  13. “Medicaid Drug Rebate Program,” CMS, https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html. ↩︎
  14. “Assuring Medicaid Beneficiaries Access to Hepatitis C (HCV) Drugs,” Medicaid Drug Rebate Program Notice, CMS, November 5, 2015, https://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Downloads/RxReleases/State-Releases/state-rel-172.pdf. ↩︎
  15. Under the rebate agreement, states may opt to not cover certain specific drugs that are listed in the statute. ↩︎
  16. Kaiser Family Foundation and Health Management Associates, Sates Focus on Quality and Outcomes Amid Waiver Changes: Results from a 50-State Medicaid Budget Survey for State Fiscal Years 2018 and 2019, https://modern.kff.org/medicaid/report/states-focus-on-quality-and-outcomes-amid-waiver-changes-results-from-a-50-state-medicaid-budget-survey-for-state-fiscal-years-2018-and-2019/ ↩︎
  17. State Maximum Allowable Costs are upper limits states apply to multiple-source drugs included on state maximum allowable cost lists. ↩︎
  18. Medicaid Drug Utilization Review State Comparison/Summary Report FFY 2014 Annual Report, Prescription Drug Fee-For Service Programs, CMS, September 2015, https://www.medicaid.gov/medicaid-chip-program-information/by-topics/prescription-drugs/downloads/2014-dur-summary-report.pdf; Medicaid Drug Utilization Review State Comparison/Summary Report FFY 2015 Annual Report, Prescription Drug Fee-For-Service Programs, CMS, December 2016, https://www.medicaid.gov/medicaid-chip-program-information/by-topics/prescription-drugs/downloads/2015-dur-summary-report.pdf; Medicaid Drug Utilization Review State Comparison/Summary Report FFY 2016 Annual Report, Prescription Drug Fee-For-Service Programs, CMS, October 2017, https://www.medicaid.gov/medicaid-chip-program-information/by-topics/prescription-drugs/downloads/2016-dur-summary-report.pdf; Medicaid Drug Utilization Review State Comparison/Summary Report FFY 2017 Annual Report, Prescription Drug Fee-For-Service Programs, CMS, October 2018, https://www.medicaid.gov/medicaid/prescription-drugs/downloads/drug-utilization-review/2017-dur-summary-report.pdf. See also “Attachment 4 – Generic Drug Substitution Policies” in state DUR Reports, https://www.medicaid.gov/medicaid/prescription-drugs/drug-utilization-review/annual-reports/index.html. ↩︎
  19. Of the states that required more the restrictive requirements, a majority required preauthorization to enable a pharmacist to provide a brand drug when a generic was available. States included other requirements, such as requiring the submission of a MedWatch Form and requiring a medical reason to override the use of a generic, and some implement more than one restrictive requirement. Ibid. ↩︎
  20. Insulin is a biologic drug that has been regulated as a small molecule drug. In March 2020, it will be regulated as biologic drug, which will allow for manufacturers to produce insulin biosimilars. “FDA ‘Confident’ that Interchangeable Insulin Will Be Available After March 2020,” FDANews Drug Daily Bulletin, December 21, 2018, https://www.fdanews.com/articles/189628-fda-confident-that-interchangeable-insulin-will-be-available-after-march-2020. ↩︎
  21. See U.S. Congress, Senate, Special Committee on Aging, Sudden Price Spikes in Off-Patent Prescription Drugs: The Monopoly Business Model that Harms Patients, Taxpayers, and the U.S. Healthcare System, December 2016, https://www.aging.senate.gov/imo/media/doc/Drug%20Pricing%20Report.pdf. ↩︎
  22. Katherine Young and Rachel Garfield. Snapshots of Recent State Initiatives in Medicaid Prescription Drug Cost Control. (Washington, DC: Kaiser Family Foundation): February 2018, https://modern.kff.org/medicaid/issue-brief/snapshots-of-recent-state-initiatives-in-medicaid-prescription-drug-cost-control/. ↩︎
  23. U.S. Congress, Senate, Committee on Finance, The Price of Sovaldi and Its Impact on the U.S. Health Care System, 114th Congress, 1st session, 2015, http://www.finance.senate.gov/imo/media/doc/1%20The%20Price%20of%20Sovaldi%20 and%20Its%20Impact%20on%20the%20U.S.%20Health%20Care%20System%20(Full%20Report).pdf. ↩︎
  24. The FDA approved Olysio (Janssen) in November 2013, Sovaldi (Gilead Sciences) in December 2013, Harvoni (Gilead Sciences) in October 2014, Viekira Pak (AbbVie) in December 2014, Technivie (AbbVie) in July 2015, Daklinza (Bristol-Myers Squibb) in July 2015, Zepatier (Merck) in January 2016, Epclusa (Gilead Sciences) in June 2016, and Mavyret (AbbVie) in August 2017. ↩︎
  25. Katherine Young. Utilization and Spending Trends in Medicaid Outpatient Prescription Drugs. Kaiser Family Foundation, February 2019, https://modern.kff.org/medicaid/issue-brief/utilization-and-spending-trends-in-medicaid-outpatient-prescription-drugs/ ↩︎
  26. Ibid. ↩︎
  27. See Andrew Mulcahy, Zachary Predmore, and Soeren Mattke, “The Cost Savings Potential of Biosimilar Drugs in the United States,” (Rand Corporation, 2014), https://www.rand.org/content/dam/rand/pubs/perspectives/PE100/PE127/RAND_PE127.pdf. ↩︎
  28. Young, op. cit. ↩︎
  29. Katherine Young, How Does the Trump Administration Drug Pricing Blueprint Affect Medicaid? Kaiser Family Foundation, May 2018, https://modern.kff.org/medicaid/issue-brief/how-does-the-trump-administration-drug-pricing-blueprint-affect-medicaid/ ↩︎
  30. Carolyn Y. Johnson, “Louisiana adopts ‘Netflix’ model to pay for hepatitis C drugs,” Washington Post, January 10, 2019, https://www.washingtonpost.com/health/2019/01/10/louisiana-adopts-netflix-model-pay-hepatitis-c-drugs/?utm_term=.b962a75edc5d. ↩︎
  31. Eric Sagnowsky, Louisiana Has Picked its ‘Netflix’ Hepatitis C Partner: Gilead’s New Generics Unit, https://www.fiercepharma.com/pharma/louisiana-picks-gilead-subsidiary-to-partner-netflix-model-for-hep-c-drugs ↩︎
  32. Martha Bebinger, Baker Outlines Steps to Lower Medicaid Drug Prices, https://www.nepr.net/post/baker-outlines-steps-lower-medicaid-drug-prices#stream/0 ↩︎
  33. Jennifer Reck, “Oklahoma Signs the Nation’s First State Medicaid Value-Based Contracts for Rx Drugs,” September 25 2018, NASHP, https://nashp.org/oklahoma-signs-first-medicaid-value-based-contracts-for-rx-drugs/. ↩︎
  34. Pfizer, Inc. v. Texas Health and Human Services Commission, and Charles Smith, Executive Commissioner, Findings and Facts and Conclusions of Law, In the United States District Court for the Western District of Texas Austin Division, Filed September 29, 2017. ↩︎
  35. Katherine Young. How Does the Trump Administration Drug Pricing Blueprint Affect Medicaid? Kaiser Family Foundation, May 2018, https://modern.kff.org/medicaid/issue-brief/how-does-the-trump-administration-drug-pricing-blueprint-affect-medicaid/ ↩︎
  36. Beginning in June 2017, the FDA has maintained a list of off-patent, off-exclusivity drugs lacking generic competition. Also in June 2017, the FDA announced it would expedite ANDA reviews until there were three generics on the market for a given brand. The agency is also intending on issuing guidance in the future addressing other activities that diminish generic competition. “FDA Tackles Drug Competition to Improve Patient Access,” FDA News Release, June 27, 2017, https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm564725.htm and Henry Waxman, Bill Corr, Kristi Martin, Sophia Duong, “What Commissioner Gottlieb’s FDA is Doing to Lower Prescription Drug Prices and Steps Congress Can Take to Help,” April 2018, https://www.commonwealthfund.org/sites/default/files/documents /___media_files_publications_issue_brief_2018_apr_waxman_gottlieb_plan_fda_ib.pdf. ↩︎
  37. Aware of the importance of biologics when considering drug costs, the FDA released the “Biologics Action Plan” in July 2018, which includes items such as providing guidance to improve biosimilar labeling and to provide clarity for manufacturers to demonstrate interchangeability, as well as providing education to health care professionals to explain concepts such as biosimilars and interchangeability “Biosimilars Action Plan: Balancing Innovation and Competition,” FDA, July 2018. See also “FDA Releases Biosimilar Action Plan,” http://www.centerforbiosimilras.com/news/fda-releases-biosimilar-action-plan. ↩︎
  38. Zachary Brennan, “FDA Sets Record for Number of Generic Drug Approvals Again,” October 11, 2018, https://www.raps.org/news-and-articles/news-articles/2018/10/fda-sets-record-number-of-generic-drug-approvals-a. ↩︎
  39. MACPAC, Improving Operations of the Medicaid Drug Rebate Program, June 2018, https://www.macpac.gov/publication/improving-operations-of-the-medicaid-drug-rebate-program/ ↩︎
  40. “Patient Affordability Value and Efficiency Act,” https://www.cassidy.senate.gov/imo/media/doc/PAVE%20Act.pdf. ↩︎
Poll Finding

Where Does Public Opinion Stand on the U.S. Role in Global Health?

Published: Apr 24, 2019

The Kaiser Family Foundation (KFF) has been tracking public opinion on the U.S. role in global health for the last decade. Now, more than two years into President Trump’s administration, the April 2019 KFF Health Tracking Poll examines whether this period, which has been marked by a changing U.S. stance toward international affairs, has shifted the public’s attitudes on these key issues. Has, for example, the administration’s promotion of an “America first” approach, which has included proposed cuts to U.S. global health programs, affected the public’s support for U.S. engagement to improve the health of those in low and middle income countries? Here we provide an overview of our latest findings, and also look at whether there have been any changes over time.

Americans’ Views on the U.S. Role in World Affairs and Global Health

NEW: About 6 in 10 Americans say the U.S. should play at least a major role in improving health for people in developing countries, though most Republicans do not. Learn more in this @KaiserFamFound #globalhealth polling data note

Consistent with previous KFF polling our latest poll finds broad support (68 percent) for the U.S. playing at least a major role in world affairs (Figure 1), and six in ten (58 percent) believing the U.S. should play a “leading role” or “major role” in improving health for people in developing countries (Figure 2). In the latter case, larger shares of Democrats (70 percent) say they want the U.S. to take at least a major role compared to Republicans (37 percent) or independents (55 percent).

Figure 1: Majority Of The Public See A Major International Role For U.S.
Figure 2: Most See A Major Role For U.S. In Improving Health In Developing Countries, Including Large Shares Of Democrats

About half of the public (49 percent) think the U.S. is spending “too much” on foreign aid, similar to previous KFF poll findings (we have also found that the public greatly overestimates what is spent on foreign aid. See: https://www.kff.org/global-health-policy/poll-finding/americans-views-on-the-u-s-role-in-global-health/). However, when asked about U.S. spending specifically on efforts to improve health in developing countries, a much smaller proportion (29 percent) say the U.S. is spending “too much,” with a majority saying U.S. spending is “about the right amount” (31 percent) or “too little” (29 percent) (Figure 3).

Figure 3: Half Say U.S. Is Spending Too Much On Foreign Aid, But Fewer Say The Same About Improving Health In Developing Countries

Americans’ Views on the Trump Administration and Global Health

In assessing the Trump administration’s efforts, nearly half (46 percent) believe it has made improving health for people in developing countries “a lower priority” compared to previous U.S. presidential administrations with few (5 percent) saying it has made it “a higher priority.” Nearly four in ten (36 percent) would like to see the Trump administration make improving health for people in developing countries “a higher priority” (Figure 4).

Figure 4: Nearly Half Say Global Health Is a Lower Priority in Trump Administration; Nearly Four in Ten Want It To Be A Higher Priority

Americans’ Views on U.S. Participation in joint efforts in global health

In terms of how the U.S. should invest in global health, more than twice as many Americans believe the U.S. should participate in joint “international efforts” to improve global health (67 percent) than say the U.S. should “operate on its own” (26 percent) (Figure 5). This holds across party, though the divide is larger among Democrats (78 percent v. 17 percent) and independents (70 percent v. 25 percent), compared to Republicans (57 percent v. 36 percent).

Figure 5: Majorities Across Parties Believe U.S. Should Participate In Joint International Efforts When Giving Aid To Improve Global Health

In fact, over the last ten years, the public has become even more in favor of U.S. participation in joint international efforts (Figure 6). In 2009, 55 percent of Americans expressed that opinion, compared to 67 percent in our most recent KFF Health Tracking Poll. The share saying the U.S. should operate on its own decreased from 39 percent to 26 percent over that same time period. These views are at odds with the current direction of the administration, which has moved to reduce U.S. engagement in joint international efforts and initiatives.

Figure 6: Public Has Become Even More In Favor Of U.S. Participation In Joint International Efforts To Improve Global Health

Evidence of Increased Partisanship regarding Support for U.S. Global Health Spending

At the same time, there has been an increasing partisan divide regarding views of U.S. spending on global health. In 2009, one-fourth (23 percent) of Republicans and one in seven (14 percent) Democrats said they felt the U.S. was spending “too much” on efforts to improve health for people in developing countries. Ten years later, the share of Republicans who express this view grew 17 percentage points (up to 40 percent) while among Democrats, the share is still about one in seven (17 percent) (Figure 7).

Figure 7: Republicans’ Views Of Global Health Spending Have Become Increasingly Negative, Widening The Partisan Divide On Issue